ClinicalTrials.gg
CompletedNCT03709680Updated Oct 7, 2026Results posted

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

A Phase 2 interventional study of Palbociclib and Temozolomide in Ewing Sarcoma, Solid Tumors and Rhabdoid Tumor, sponsored by Pfizer. Completed at 84 sites in 13 countries. Open to participants aged 2 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Updated Oct 7, 2026Now CompletedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
2 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing temozolomide in Sarcoma, Ewing — 3 open to participants now, 5 under way, none of them phase 3. Temozolomide · Sarcoma, Ewing.

Enrollment
Largest of 14
128 · median 39
Started
2019
the only one that year
Phase 2
8 of 14
1 open now
Registered
9th of 14
by date
Lead sponsor
1 of 14
Pfizer

Among the 14 studies testing temozolomide in Sarcoma, Ewing, this one has the largest enrollment, is the only one that started in 2019, is one of 8 in phase 2, and was the 9th registered.

Sarcoma, Ewing

250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.

Browse Sarcoma, Ewing studies →

Open to participants now

3 of the 14 studies testing temozolomide in Sarcoma, Ewing are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing temozolomide in Sarcoma, Ewing, or all of them as a file.
02

Study summary

A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescents, and young adults with recurrent or refractory Ewing sarcoma (EWS).

03

Conditions studied

  • Ewing Sarcoma
  • Solid Tumors
  • Rhabdoid Tumor
  • Rhabdomyosarcoma
  • Neuroblastoma
  • Medulloblastoma
  • Diffuse Intrinsic Pontine Glioma

Keywords

  • Ewing Sarcoma
  • EWS
  • Neuroblastoma
  • Recurrent Neuroblastoma
  • Solid Tumor
  • Recurrent Solid Tumors
  • Refractory Solid Tumors
  • Bone Cancer
  • Bone Tumor
  • Bone Sarcoma
  • Soft Tissue Cancer
  • Soft Tissue Sarcoma
  • Recurrent Ewing Sarcoma
  • Refractory Ewing Sarcoma
  • Relapsed Ewing Sarcoma
  • Pediatric Cancer
  • Childhood Cancer
  • Ewing Sarcoma Treatment
  • Palbociclib
  • CDK4/6 Inhibitor
  • Irinotecan
  • Temozolomide
  • Topotecan
  • Cyclophosphamide
04

Who can participate

Ages eligible
2 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed solid tumor as follows:

    • For dose escalation and dose determination parts: Histologically confirmed relapsed or refractory solid tumor (including CNS tumors but not lymphomas). Patients with Diffuse Intrinsic Pontine Glioma do not require histological only radiographic confirmed relapse to enroll.
    • For dose expansion and tumor specific cohorts: Histologically confirmed relapsed or refractory solid tumor including but not limited to EWS, rhabdoid tumor, rhabdomyosarcoma, neuroblastoma, and medulloblastoma. Patients with Diffuse Intrinsic Pontine Glioma do not require histological only radiographic confirmed relapse to enroll. EWS is not eligible for TOPO and CTX tumor-specific cohorts.
    • For randomized Phase 2 part: Histologically confirmed Ewing sarcoma at diagnosis or at relapse, with presence of EWSR1-ETS or FUS-ETS rearrangement. Histopathology confirmation of both EWSR1-ETS or FUS-ETS rearrangement partners is required OR availability of formalin fixed paraffin embedded (FFPE) tumor tissue sample for central testing. Patient must have relapsed or have refractory disease and at least evaluable disease in at least one site other than bone marrow that can be followed by imaging.
  2. Age ≥2 and \<21 years at the time of study entry.
  3. Lansky performance status ≥50% for patients ≤16 years of age, or (ECOG) 0, 1 or 2 for patients >16 years of age.
  4. Adequate bone marrow function.

    • ≥1000/mm3;
    • count ≥75,000/mm3 (transfusion independent, no platelet transfusion in past 7 days prior study entry);
    • ≥8.5 g/dL (transfusion allowed).
  5. Adequate renal function: Serum creatinine level based on age/gender must within protocol specified limits.
  6. Adequate liver function, including:

    • (AST) and alanine aminotransferase (ALT)

      ≤2.5 × (ULN) or ≤5 × ULN for age, if attributable to disease involvement of the liver;

    • Total ≤1.5 × ULN for age, unless the patient has documented Gilbert's syndrome.Patients with documented Gilbert's syndrome are eligible if direct bilirubin is within normal ranges (≤ULN).
  7. Patients enrolled to Phase 1 portion of the study and tumor specific cohorts must have as defined by version 1.1 or modified RANO criteria for CNS disease or at least evaluable disease by INRC for neuroblastoma.

    The eligible patients with neuroblastoma must have at least one of the following at the time of study entry:

    • Measurable tumor by CT or MRI that is avid on MIBG scan or demonstrates increased FDG uptake on PET scan;
    • Avid lesion on MIBG scan with positive uptake at a minimum of one site;
    • For disease that is not avid by MIBG-scan, at least one lesion that demonstrates increased FDG uptake on PET scan AND viable neuroblastoma confirmed by current or prior ;
    • bone marrow involvement with more than 5% neuroblastoma cells in at least one sample from bilateral bone marrow biopsies;
    • In non MIBG-avid refractory soft tissue disease that does not demonstrate increased FDG uptake; lesion biopsy is required to document the presence of viable neuroblastoma, unless patient has a new soft tissue lesion (radiographic evidence of disease progression).

    Patients with EWS enrolled to Phase 2 portion of the study are eligible with evaluable disease (eg, bone only disease with no soft tissue component).

  8. Recovered to Grade ≤1, or to baseline, from any non-hematological acute toxicities of prior surgery, chemotherapy, immunotherapy, radiotherapy, differentiation therapy or biologic therapy, with the exception of alopecia.
  9. Serum/urine pregnancy test (for all girls ≥8 years of age) negative at screening and at the baseline visit.

Exclusion criteria

Exclusion:

  1. Phase 1 and tumor specific cohorts: For palbociclib with IRN and TMZ combination, prior treatment with a CDK4/6 inhibitor or progression while on treatment with an IRN-containing regimen that includes TMZ. Patients who have received the combination of IRN and TMZ and did not progress while on these medications are eligible. For patients enrolling in the palbociclib with TOPO and CTX combination, prior treatment with a CDK4/6 inhibitor or progression while on treatment with a TOPO-containing regimen that includes CTX. Patients who have received the combination of TOPO and CTX and did not progress while on these medications are eligible. Phase 2 portion: prior treatment with a CDK4/6 inhibitor or progression while on treatment with an IRN-containing or TMZ-containing regimen. Patients who have received IRN and/or TMZ and did not progress while on these medications are eligible.
  2. Prior intolerability to IRN and/or TMZ plus/minus palbociclib with IRN and TMZ combination and prior intolerability to TOPO and/or CTX for TOPO and CTX combination. For patients enrolled in the UK, any for IRN and/or TMZ treatment, as per the local SmPC.
  3. Use of strong cytochrome P450 (CYP) 3A inhibitors or inducers within 12 days of study entry. Patients who are receiving strong uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) inhibitors within 12 days of Cycle 1 Day 1 (C1D1) are not eligible for the palbociclib with IRN and TMZ combination. Patients who are receiving strong UGT1A1 inhibitors within 12 days of C1D1 are eligible for the palbociclib with TOPO and CTX combination (See Section 5.7.1 for list of products.)
  4. Systemic anti cancer therapy within 2 weeks prior to study entry and 6 weeks for nitrosoureas.
  5. Prior irradiation to >50% of the bone marrow (see Appendix 9).
  6. Participation in other studies involving drug(s) within 2 weeks or 5 half lives, whichever is longer, prior to study entry.
  7. Major surgery within 4 weeks prior to study entry. Surgical or central line placement are not considered major surgeries.
  8. For IRN and TMZ with/without palbociclib combinations: known or suspected to palbociclib, dacarbazine, IRN and/or TMZ. For combination of palbociclib with TOPO and CTX: known or suspected hypersensitivity to palbociclib, TOPO and/or CTX.
  9. Patients with known symptomatic brain tumors or and require , unless they have been on a stable or on a decreasing steroid dose for >14 days.
  10. Patients with previously diagnosed brain metastases are eligible if they have completed their prior treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry for these for at least 14 days post radiation and 4 weeks post-surgery and are neurologically stable.
  11. Hereditary bone marrow failure disorder.
  12. >470 msec.
  13. History of or uncontrolled cardiac disease, including:

    • History of or active congestive heart failure; if patient had congestive heart failure resolve and >1 year from resolution, patient will be considered eligible;
    • Clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation or Torsades de Pointes);
    • Diagnosed or suspected congenital or acquired prolonged QT syndrome;
    • Need for medications known to prolong the QT interval;
    • Uncorrected hypomagnesemia or hypokalemia because of potential effects on the QT interval;
    • \<50% or shortening fraction \<28%.
  14. Recent or ongoing clinically significant gastrointestinal disorder that may interfere with absorption of orally administered drugs (eg, gastrectomy).
  15. Evidence of serious active or uncontrolled bacterial, fungal or viral infection or known history of virus, virus, or infection or acquired immunodeficiency syndrome-related illness. Screening for viral hepatitis and HIV is under discretion of investigator unless required by local regulation.
  16. Severe acute or chronic medical or laboratory test abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results, and in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
  17. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  18. Fertile male patients or female patients of who are unwilling or unable to follow requirements.
  19. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    Phase 1 Tumor specific cohort - Neuroblastoma

    Palbociclib in combination with topotecan and cyclophosphamide.

    Drug: Palbociclib · Drug: Topotecan · Drug: Cyclophosphamide

  • Experimental
    Phase 1

    Palbociclib in combination with temozolomide and irinotecan and/or with topotecan and cyclophosphamide.

    Drug: Palbociclib · Drug: Temozolomide · Drug: Irinotecan · Drug: Topotecan · Drug: Cyclophosphamide

  • Experimental
    Phase 2 Arm A

    Palbociclib in combination with irinotecan and temozolomide.

    Drug: Palbociclib · Drug: Temozolomide · Drug: Irinotecan

  • Active comparator
    Phase 2 Arm B

    Irinotecan and temozolomide alone.

    Drug: Temozolomide · Drug: Irinotecan

Interventions

  • Phase 1: Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2, or 95 mg/m2 or 115 mg/m2 on days 1-14 of a 21-day cycle Phase 1 Tumor specific cohort-Neuroblastoma and Phase 2 : Administered (oral) at 75 mg/m2 on days 1-14 of a 21-day cycle

    Also known as: Ibrance

  • Phase 1 and Phase 2: Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle

    Also known as: Temodar

  • Phase 1 and Phase 2: Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

    Also known as: Campto

  • Phase 1 only : Administered at 0.75 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

    Also known as: Hycamtin

  • Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle

    Also known as: Cytoxan

06

What researchers measure

Primary outcomes

  1. Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT was an adverse event (AE) occurring in the first cycle of treatment which were attributable to at least one of the agents in the combination that met the defined criteria of study per Sponsor. An AE we defined as any untoward medical occurrence in a study participant who received study drug without regard to possibility of causal relationship. AEs determined as DLT were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: Cycle 1 (21 days)

  2. Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Treatment-emergent AEs, Treatment-emergent Serious AEs (SAEs), Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)

  3. Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Hematology Parameters

    Hematology parameters included activated partial thromboplastin time prolonged, anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased and increased, neutrophil count decreased, platelet count decreased. Grades by CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening and Grade 5= death related to AE; Grade 0= non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)

  4. Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters

    Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)

  5. Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in Electrocardiogram (ECG) Parameters

    ECG parameters included PR interval, QRS complex, QT interval, Bazett's correction QT (QTcB) interval and Fridericia's correction (QTcF) interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters were recorded.

    Time frame: Baseline (pre-treatment) up to Cycle 3 (63 days)

  6. Phase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure

    Blood pressure evaluation included systolic blood pressure (SBP) and diastolic blood pressure (DBP). SBP and DBP were measured in the sitting position after participant had been in the supine position for approximately 2 minutes.

    Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 24.2 months)

  7. Phase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate

    Pulse rate was measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.

    Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)

  8. Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Clinically Significant Changes in Glycosylated Hemoglobin (HbA1c)

    HbA1c is a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Clinical significance was determined based on investigator

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)

  9. Phase 1, Dose Expansion Cohorts: Objective Response (OR) Rate Based on Investigator Assessment

    OR: best overall response(BOR) of confirmed complete response(CR) or partial response(PR) per response evaluation criteria in solid tumors(RECIST)v1.1 (CR:complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm),no new lesion;PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions,no new lesion) or modified revised assessment for neuro-oncology(RANO) for central nervous system malignancies (CR:disappearance of all target lesions,no new lesion;PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value,no new lesion);international neuroblastoma response criteria(INRC)for neuroblastoma also included minor response(MR)(Per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow). OR rate:percentage of participants with BOR of CR or PR;CR or PR or MR.

    Time frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months

  10. TSC: OR Rate Based on Investigator Assessment

    OR: BOR of confirmed CR or PR or MR assessed by investigator per INRC for neuroblastoma. There were different criteria for CR and PR as specified in protocol for the following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow. Overall CR: All components met criteria for CR; PR: PR in at least 1 component and all other components were either CR, minimal disease (MD) \[bone marrow\], PR (soft tissue or bone) or not involved; no component with progressive disease (PD) and MR: PR or CR in at least one component but at least one other component with stable disease (SD); no component with PD. OR rate was presented as percentage of participants with BOR of CR or PR or MR.

    Time frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months

  11. Phase 2: Event Free Survival (EFS) Based on Investigator Assessment

    EFS: time from date of randomization to the date of first documentation of any of the following events based on investigator assessment: objective PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.

    Time frame: From date of randomization up to objective PD, diagnosis of secondary malignancy or death, whichever occurred first (maximum of approximately 14 months)

Secondary outcomes

  1. Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, and Maximum Grade 3 or 4 and 5 AEs by CTCAE v4.03

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)

  2. Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Hematology Parameters

    Hematology parameters included activated partial thromboplastin time prolonged, anemia, hemoglobin increased, INR increased, lymphocyte count decreased and increased, neutrophil count decreased, platelet count decreased. Grades by CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening and, Grade 5= death related to AE; Grade 0= non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Only those parameters are reported which had at least 1 participant for any reporting group.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)

  3. Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters

    Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and, Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Only those parameters are reported which had at least 1 participant for any reporting group.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)

  4. Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG Parameters

    ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTc interval, QTcB interval and QTcF interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters are recorded.

    Time frame: Baseline (pre-treatment) up to Cycle 3 (63 days)

  5. Phase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure

    Blood pressure evaluation included SBP and DBP. SBP and DBP were measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.

    Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)

  6. Phase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate

    Pulse rate was measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.

    Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)

  7. Phase 1: Maximum Plasma Concentration (Cmax) at Steady-State of Palbociclib, TMZ, IRN, SN-38, CTX and TOPO

    Cmax was observed directly from data. Active metabolite of IRN is 7-Ethyl-10-hydroxycamptothecin (SN-38). In this outcome measure, Cmax was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

    Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5

  8. Phase 1: Time to Reach Cmax (Tmax) of Palbociclib, TMZ, IRN SN-38, CTX and TOPO

    Tmax was defined as time for Cmax. Active metabolite of IRN is SN-38. In this outcome measure, Tmax was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI. As pre-specified in protocol, time points in time frame could have a window of +/- 20% of the sampling time.

    Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5

  9. Phase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) of Palbociclib, TMZ, IRN SN-38, CTX and TOPO

    Area under the concentration-time profile from time zero to the time tau. AUCtau was determined using the linear/log trapezoidal method. Active metabolite of IRN is SN-38. In this outcome measure, AUCtau was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

    Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5

  10. Phase 1: Pre-dose Plasma Concentration (Ctrough) at Steady-State of Palbociclib, TMZ, IRN SN-38, CTX and TOPO

    Ctrough was defined as pre-dose plasma concentration during multiple dosing and observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Ctrough was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D.

    Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5 or TMZ IV- PRD C1D5, C2D5

  11. Phase 1: Clearance of Palbociclib, TMZ, IRN SN-38, CTX and TOPO

    Clearance of a drug is a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Active metabolite of IRN is SN-38. In this outcome measure, clearance was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. For IV administration CL/F was reported while for oral CL was reported. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

    Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5

  12. Phase 1, Dose Escalation/Dose Determination Cohorts: OR Rate Based on Investigator Assessment

    OR: BOR of confirmed CR or PR per RECIST v1.1 \[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm), no new lesion;PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\]or RANO for central nervous system malignancies\[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value, no new lesion\]; INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. OR rate: percentage of participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.

    Time frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months

  13. Phase 1, Dose Escalation/Dose Determination Cohorts: Duration of Response (DOR) Based on Investigator Assessment

    DOR was defined for participants with OR:time from the date of first documentation of OR to the date of first documentation of PD or death due to any cause. OR: BOR of confirmed CR or PR per RECIST v1.1\[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm),no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\] or RANO for central nervous system malignancies \[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value, no new lesion\]; INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. OR rate: % participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.

    Time frame: From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)

  14. Phase 1, Dose Expansion Cohorts and TSC: DOR Based on Investigator Assessment

    DOR for participants with OR: time from the date of first documentation of OR to the date of first documentation of PD or death due to any cause. OR: BOR of confirmed CR or PR per RECIST v1.1 \[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\] or RANO for central nervous system malignancies \[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. of target lesions, compared to baseline value, no new lesion\]; OR rate: % participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.

    Time frame: From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)

  15. Phase 1, Dose Expansion Cohorts and TSC: Progression-Free Survival (PFS) Based on Investigator Assessment

    PFS: time from date of first dose of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever occurred first. Per RECIST, PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Per RANO, PD: \>=25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product; the appearance of one or more new lesions, worsening neurologic status not explained by causes unrelated to tumor progression; any increase in tumor cross-sectional area (tumor volume). Per INRC for neuroblastoma as specified in protocol different PD criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow; overall PD was when any component fulfilled criteria of PD. Kaplan-Meier method was used for evaluation.

    Time frame: First dose of study treatment (Day 1) up to objective PD or death due to any cause, whichever occurred first (maximum of approximately 25 months)

  16. Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS)

    OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.

    Time frame: First dose of study treatment (Day 1) up to death due to any cause (maximum of approximately 25 months)

  17. Phase 2: Event-Free Survival (EFS) Based on Blinded Independent Review Committee (BIRC) Assessment

    EFS: time from date of randomization to the date of first documentation of any of the following events based on investigator assessment: objective PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.

    Time frame: First date of randomization to the date of first objective PD, diagnosis of secondary malignancy, death due to any cause (maximum of approximately 14 months)

  18. Phase 2: OR Rate Based on Investigator Assessment

    OR: BOR of CR or PR per RECIST v1.1. CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion. OR rate was percentage of participants with BOR of CR or PR.

    Time frame: First dose of study treatment (Day 1) up to maximum of approximately 14 months

  19. Phase 2: Comparison of Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Assessment With Magnetic Resonance Imaging (MRI)/ Computed Tomography (CT) Assessment for OR

    CR or PR per RECIST v1.1. CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion. PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD= stable disease, NE= Not Evaluable.

    Time frame: Cycle 4

  20. Phase 2: PFS Based on Investigator Assessment

    PFS: time from date of first dose of study treatment to the date of the first documentation of PD or death due to any cause. Per RECIST v1.1, PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.

    Time frame: First dose of study treatment (Day 1) up to PD or death due to any cause, whichever occurred (maximum of approximately 14 months)

  21. Phase 2: OS

    OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.

    Time frame: First dose of study treatment (Day 1) up to date of death due to any cause (maximum of approximately 76 months)

  22. Phase 2: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 9.5 months)

  23. Phase 2: Cmax at Steady-State of Palbociclib, TMZ, IRN and SN-38

    Cmax was observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Cmax was reported only for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

    Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5

  24. Phase 2: Tmax of Palbociclib, TMZ, IRN and SN-38

    Tmax was defined as time for Cmax. Active metabolite of IRN is SN-38. In this outcome measure, Tmax was reported only for Phase 2: reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

    Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5

  25. Phase 2: AUCtau,ss of Palbociclib, TMZ, IRN and SN-38

    Area under the concentration-time profile from time zero to the time tau. AUCtau was determined using the linear/log trapezoidal method. Active metabolite of IRN is SN-38. In this outcome measure, AUCtau was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

    Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5

  26. Phase 2: Ctrough at Steady-State of Palbociclib, TMZ, IRN and SN-38

    Ctrough was defined as pre-dose plasma concentration during multiple dosing and observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Ctrough was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D.

    Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38 : PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5; or TMZ IV- PRD C1D5, C2D5

  27. Phase 2: Clearance of Palbociclib, TMZ, IRN and SN-38

    Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Active metabolite of IRN is SN-38. In this outcome measure, clearance was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. For IV administration CL/F was reported while for oral administration CL was reported. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

    Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5

  28. Phase 2: Change From Baseline of Patient Reported Outcomes (PROMIS) Parent Proxy Profile v2.0 - Profile-25 Scale Score for Age >=5 to <=17 Years at Cycles 2 and 4

    PROMIS Parent Proxy Profile V2.0 - Profile-25 instrument in this outcome measure was intended for parents serving as proxy reporters for their child (youth ages 5-17). The Profile-25 was a collection of short forms containing 4 items from six PROMIS domains (depressive symptoms, anxiety, physical function-mobility, pain interference, fatigue, and peer relationships with scores ranged from 20 to 80; where 20 = better health and 80 = worse health and for peer relationship 80 to 20; where 80 = better health and 20 = worse health along with a single item on pain intensity with 11 levels of responses from 0 (no pain) to 10 (worst pain you can think of).

    Time frame: Baseline, Cycles 2 and 4

  29. Phase 2: Change From Baseline of PROMIS Pediatric Profile v2.0 - Profile-25 Scale Score for Age >=8 to <=17 Years at Cycles 2 and 4

    PROMIS Parent Proxy Profile V2.0 - Profile-25 instrument in this outcome measure was intended for parents serving as proxy reporters for their child (youth ages 5-17). The Profile-25 was a collection of short forms containing 4 items from six PROMIS domains (depressive symptoms, anxiety, physical function-mobility, pain interference, fatigue, and peer relationships with each item having 5 levels of responses (1=Never, 2=Almost never, 3=Sometimes, 4=Often, and 5=Almost always) along with a single item on pain intensity with 11 levels of responses from 0 (No pain) to 10 (Worst pain you can think of).

    Time frame: Baseline, Cycles 2 and 4

  30. Phase 2: Change From Baseline of PROMIS-29 Profile v2.1 Scale Score for Age >=18 Years at Cycles 2 and 4

    PROMIS Profile-29 had eight domains (ability to participate in social roles, anxiety, depression, fatigue, pain Intensity, pain Interference, physical function, sleep disturbance). There were four items for each domain except pain intensity which had only 1 item. All items (except pain intensity) had a score of 1 to 5, when scores from each item was summed, it resulted to score ranged from 4 to 20, (except for pain intensity, where it is 1 to 10, highest score = worst pain), where for physical function highest score = without any difficulty and lowest score = unable to do; anxiety, depression, fatigue highest score = always and lowest score = never; sleep disturbance highest score = not at all, lowest score = very much; ability to participate in social roles and activities (trouble) highest score = never and lowest score = always; pain interference highest score = very much and lowest score = not at all.

    Time frame: Baseline, Cycles 2 and 4

  31. Phase 2: Average Days of Hospitalization

    Hospitalization included planned and unplanned inpatient admissions regardless the reason.

    Time frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months

Other outcomes

  1. Phase 1 TSC: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters - Upto Study Completion Date

    Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 24.2 months)

  2. Phase 1 TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG Parameters - Upto Study Completion Date

    ECG parameters included PR interval, QRS interval, QT interval, Bazett's correction QT (QTcB) interval and Fridericia's correction (QTcF) interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters were recorded.

    Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 24.2 months)

  3. Phase 1 TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure (Upto Study Completion Date)

    Blood pressure evaluation included systolic blood pressure (SBP) and diastolic blood pressure (DBP). SBP and DBP were measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.

    Time frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 24.2 months)

  4. Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS) - Upto Study Completion Date

    OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.

    Time frame: First dose of study treatment (Day 1) up to death due to any cause (maximum of approximately 26 months)

  5. Phase 2: OS - Upto Study Completion Date

    OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.

    Time frame: First dose of study treatment (Day 1) up to date of death due to any cause (maximum up to 76 months of treatment exposure)

07

Results

Posted Oct 7, 2026
Limitations and caveats
Due to character limit issue in baseline section analysis population description , N is expanded here = Overall Number of Participants Analyzed.

Participant flow

In this study there was: Phase 1- had dose escalation/determination cohorts followed by dose expansion cohorts and if eligibility as pre-specified in protocol was met then tumor-specific cohort (TSC) was conducted; Phase 2- compared the efficacy of palbociclib in combination with Irinotecan (IRN) and Temozolomide (TMZ) versus IRN and TMZ alone.

Phase-1(Escalation-Expansion):Treatment
Participant flow — Phase-1(Escalation-Expansion):Treatment
MilestonePhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Started17466602000
Full analysis set (fas)17466602000
Safety analysis set (sas)17466602000
Completed000000100
Not completed17466601900
Withdrew: Adverse event101000100
Withdrew: Withdrawal by subject001000100
Withdrew: Withdrawal by parent/guardian100020000
Withdrew: Global deterioration of health status100100200
Withdrew: Progressive disease13445401200
Withdrew: Other100000200
Withdrew: Protocol violation000000100
Phase-1(Escalation-Expansion): Follow-up
Participant flow — Phase-1(Escalation-Expansion): Follow-up
MilestonePhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Started15345501800
Completed300210100
Not completed12343401700
Withdrew: Withdrawal by subject010000200
Withdrew: Withdrawal by parent/guardian000100000
Withdrew: Death12242301300
Withdrew: Other000010200
TSC: Treatment
Participant flow — TSC: Treatment
MilestonePhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Started000007000
Fas000007000
Sas000007000
Completed000001000
Not completed000006000
Withdrew: Withdrawal by parent/guardian000002000
Withdrew: Progressive disease000003000
Withdrew: Other000001000
TSC: Follow-up
Participant flow — TSC: Follow-up
MilestonePhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Started000007000
Completed000001000
Not completed000006000
Withdrew: Withdrawal by subject000001000
Withdrew: Death000002000
Withdrew: Study terminated by sponsor000001000
Withdrew: Other000002000
Phase 2: Treatment
Participant flow — Phase 2: Treatment
MilestonePhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Started00000004221
Fas00000004221
Sas00000004121
Completed000000000
Not completed00000004221
Withdrew: Adverse event000000022
Withdrew: Progressive disease00000003112
Withdrew: Withdrawal by subject000000001
Withdrew: Withdrawal by parent/guardian000000034
Withdrew: Other000000062
Phase 2: Follow-up
Participant flow — Phase 2: Follow-up
MilestonePhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Started00000003721
Completed000000041
Not completed00000003320
Withdrew: Death00000002615
Withdrew: Progressive disease000000001
Withdrew: Withdrawal by subject000000010
Withdrew: Withdrawal by parent/guardian000000012
Withdrew: Study terminated by sponsor000000051
Withdrew: Other000000001

Outcome measures

PrimaryPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)

DLT was an adverse event (AE) occurring in the first cycle of treatment which were attributable to at least one of the agents in the combination that met the defined criteria of study per Sponsor. An AE we defined as any untoward medical occurrence in a study participant who received study drug without regard to possibility of causal relationship. AEs determined as DLT were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Time frame:
Cycle 1 (21 days)
Reported as:
Count of participants · Participants
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)0021
PrimaryPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Treatment-emergent AEs, Treatment-emergent Serious AEs (SAEs), Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Reported as:
Count of participants · Participants
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Treatment-emergent AEs, Treatment-emergent Serious AEs (SAEs), Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5
ParticipantsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Participants With Treatment emergent AEs17207
Participants With Treatment -emergent SAEs8104
Participants With Treatment Related AEs17207
Participants With Treatment Related SAEs382
Participants With Maximum Grade 3 or 4 AEs14197
Participants With Maximum Grade 5 AEs100
PrimaryPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Hematology Parameters

Hematology parameters included activated partial thromboplastin time prolonged, anemia, hemoglobin increased, international normalized ratio (INR) increased, lymphocyte count decreased and increased, neutrophil count decreased, platelet count decreased. Grades by CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening and Grade 5= death related to AE; Grade 0= non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Reported as:
Count of participants · Participants
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Hematology Parameters
ParticipantsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Activated partial thromboplastin time prolonged — Grade 00——
Activated partial thromboplastin time prolonged — Grade 10——
Activated partial thromboplastin time prolonged — Grade 20——
Activated partial thromboplastin time prolonged — Grade 31——
Activated partial thromboplastin time prolonged — Grade 4NA——
Anemia — Grade 0000
Anemia — Grade 1600
Anemia — Grade 2551
Anemia — Grade 36156
Anemia — Grade 4NANANA
Hemoglobin increased — Grade 014197
Hemoglobin increased — Grade 1300
Hemoglobin increased — Grade 2000
Hemoglobin increased — Grade 3010
Hemoglobin increased — Grade 4NANANA
INR increased — Grade 01——
INR increased — Grade 10——
INR increased — Grade 20——
INR increased — Grade 30——
INR increased — Grade 4NA——
Lymphocyte count decreased — Grade 0300
Lymphocyte count decreased — Grade 1300
Lymphocyte count decreased — Grade 2320
Lymphocyte count decreased — Grade 3872
Lymphocyte count decreased — Grade 40115
Lymphocyte count increased — Grade 016185
Lymphocyte count increased — Grade 1NANANA
Lymphocyte count increased — Grade 2120
Lymphocyte count increased — Grade 3002
Lymphocyte count increased — Grade 4NANANA
Neutrophil count decreased — Grade 0121
Neutrophil count decreased — Grade 1010
Neutrophil count decreased — Grade 2221
Neutrophil count decreased — Grade 3841
Neutrophil count decreased — Grade 46114
Platelet count decreased — Grade 0500
Platelet count decreased — Grade 1810
Platelet count decreased — Grade 2261
Platelet count decreased — Grade 3210
Platelet count decreased — Grade 40126
PrimaryPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters

Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Reported as:
Count of participants · Participants
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters
ParticipantsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Alanine aminotransferase increased — Grade 013152
Alanine aminotransferase increased — Grade 1134
Alanine aminotransferase increased — Grade 2110
Alanine aminotransferase increased — Grade 3211
Alanine aminotransferase increased — Grade 4000
Alkaline phosphatase increased — Grade 012135
Alkaline phosphatase increased — Grade 1362
Alkaline phosphatase increased — Grade 2210
Alkaline phosphatase increased — Grade 3000
Alkaline phosphatase increased — Grade 4000
Aspartate aminotransferase increased — Grade 013151
Aspartate aminotransferase increased — Grade 1245
Aspartate aminotransferase increased — Grade 2011
Aspartate aminotransferase increased — Grade 3200
Aspartate aminotransferase increased — Grade 4000
Blood bilirubin increased — Grade 017187
Blood bilirubin increased — Grade 1020
Blood bilirubin increased — Grade 2000
Blood bilirubin increased — Grade 3000
Blood bilirubin increased — Grade 4000
Creatinine increased — Grade 0111
Creatinine increased — Grade 112184
Creatinine increased — Grade 2312
Creatinine increased — Grade 3100
Creatinine increased — Grade 4000
GGT increased — Grade 00—1
GGT increased — Grade 10—0
GGT increased — Grade 21—0
GGT increased — Grade 30—0
GGT increased — Grade 40—0
Hypercalcemia — Grade 016207
Hypercalcemia — Grade 1000
Hypercalcemia — Grade 2000
Hypercalcemia — Grade 3000
Hypercalcemia — Grade 4100
Hyperglycemia — Grade 015176
Hyperglycemia — Grade 1131
Hyperglycemia — Grade 2000
Hyperglycemia — Grade 3100
Hyperglycemia — Grade 4000
Hyperkalemia — Grade 016196
Hyperkalemia — Grade 1011
Hyperkalemia — Grade 2100
Hyperkalemia — Grade 3000
Hyperkalemia — Grade 4000
Hypermagnesemia — Grade 015174
Hypermagnesemia — Grade 1223
Hypermagnesemia — Grade 2NANANA
Hypermagnesemia — Grade 3010
Hypermagnesemia — Grade 4000
Hypernatremia — Grade 017207
Hypernatremia — Grade 1000
Hypernatremia — Grade 2000
Hypernatremia — Grade 3000
Hypernatremia — Grade 4000
Hypoalbuminemia — Grade 012124
Hypoalbuminemia — Grade 1482
Hypoalbuminemia — Grade 2001
Hypoalbuminemia — Grade 3100
Hypoalbuminemia — Grade 4NANANA
Hypocalcemia — Grade 015173
Hypocalcemia — Grade 1234
Hypocalcemia — Grade 2000
Hypocalcemia — Grade 3000
Hypocalcemia — Grade 4000
Hypoglycemia — Grade 015187
Hypoglycemia — Grade 1120
Hypoglycemia — Grade 2000
Hypoglycemia — Grade 3100
Hypoglycemia — Grade 4000
Hypokalemia — Grade 014115
Hypokalemia — Grade 1NANANA
Hypokalemia — Grade 2391
Hypokalemia — Grade 3001
Hypokalemia — Grade 4000
Hypomagnesemia — Grade 014147
Hypomagnesemia — Grade 1360
Hypomagnesemia — Grade 2000
Hypomagnesemia — Grade 3000
Hypomagnesemia — Grade 4000
Hyponatremia — Grade 09133
Hyponatremia — Grade 1874
Hyponatremia — Grade 2NANANA
Hyponatremia — Grade 3000
Hyponatremia — Grade 4000
Hypophosphatemia — Grade 014124
Hypophosphatemia — Grade 1243
Hypophosphatemia — Grade 2140
Hypophosphatemia — Grade 3000
Hypophosphatemia — Grade 4000
PrimaryPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in Electrocardiogram (ECG) Parameters

ECG parameters included PR interval, QRS complex, QT interval, Bazett's correction QT (QTcB) interval and Fridericia's correction (QTcF) interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters were recorded.

Time frame:
Baseline (pre-treatment) up to Cycle 3 (63 days)
Reported as:
Count of participants · Participants
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in Electrocardiogram (ECG) Parameters
ParticipantsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
PR Interval (milli second [msec]) Value greater than equal to (>=)300000
PR Interval (msec) %Change>=25% and Baseline > 200000
PR Interval (msec) %Change>=50% and Baseline <=200000
QRS Interval (msec) Value >=200000
QRS Interval (msec) %Change>=25% and Baseline >= 100011
QRS Interval (msec) %Change>=50% and Baseline < 100110
QT Interval (msec) Value less than equal to (<=)45017197
QT Interval (msec) 450<Value<=480000
QT Interval (msec) 480<Value<=500000
QT Interval (msec) >500010
QT Interval (msec) Change<=306163
QT Interval (msec) 30<Change<=60721
QT Interval (msec) Change>60420
QTcB (msec) Value<=450884
QTcB (msec) 450<Value<=480583
QTcB (msec) 480<Value<=500320
QTcB (msec) Value>500120
QTcB (msec) Change<=3012132
QTcB (msec) 30<Change<=60552
QTcB (msec) Change>60020
QTcF (msec) Value<=45013177
QTcF (msec) 450<Value<=480420
QTcF (msec) 480<Value<=500000
QTcF (msec) Value>500010
QTcF (msec) Change<=3011152
QTcF (msec) 30<Change<=60642
QTcF (msec) Change>60010
PrimaryPhase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure

Blood pressure evaluation included systolic blood pressure (SBP) and diastolic blood pressure (DBP). SBP and DBP were measured in the sitting position after participant had been in the supine position for approximately 2 minutes.

Time frame:
Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 24.2 months)
Reported as:
Mean · millimeters of mercury
Phase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure
millimeters of mercuryPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
SBP-3.2 ± 19.066.2 ± 16.135.4 ± 21.54
DBP-2.2 ± 16.834.2 ± 17.71-5.3 ± 13.66
PrimaryPhase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate

Pulse rate was measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.

Time frame:
Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
Reported as:
Mean · Beats per minute
Phase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate
Beats per minutePhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate-7.0 ± 26.460.1 ± 29.51.0 ± 27.78
PrimaryPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Clinically Significant Changes in Glycosylated Hemoglobin (HbA1c)

HbA1c is a form of hemoglobin which was measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Clinical significance was determined based on investigator

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Reported as:
Count of participants · Participants
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Clinically Significant Changes in Glycosylated Hemoglobin (HbA1c)
ParticipantsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Expansion Cohorts and TSC: Number of Participants With Clinically Significant Changes in Glycosylated Hemoglobin (HbA1c)000
PrimaryPhase 1, Dose Expansion Cohorts: Objective Response (OR) Rate Based on Investigator Assessment

OR: best overall response(BOR) of confirmed complete response(CR) or partial response(PR) per response evaluation criteria in solid tumors(RECIST)v1.1 (CR:complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm),no new lesion;PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions,no new lesion) or modified revised assessment for neuro-oncology(RANO) for central nervous system malignancies (CR:disappearance of all target lesions,no new lesion;PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value,no new lesion);international neuroblastoma response criteria(INRC)for neuroblastoma also included minor response(MR)(Per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow). OR rate:percentage of participants with BOR of CR or PR;CR or PR or MR.

Time frame:
First dose of study treatment (Day 1) up to maximum of approximately 25 months
Reported as:
Number · Percentage of Participants
Phase 1, Dose Expansion Cohorts: Objective Response (OR) Rate Based on Investigator Assessment
Percentage of ParticipantsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Expansion Cohorts: Objective Response (OR) Rate Based on Investigator Assessment11.8 (3.3 to 34.3)10.0 (2.8 to 30.1)
PrimaryTSC: OR Rate Based on Investigator Assessment

OR: BOR of confirmed CR or PR or MR assessed by investigator per INRC for neuroblastoma. There were different criteria for CR and PR as specified in protocol for the following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow. Overall CR: All components met criteria for CR; PR: PR in at least 1 component and all other components were either CR, minimal disease (MD) \[bone marrow\], PR (soft tissue or bone) or not involved; no component with progressive disease (PD) and MR: PR or CR in at least one component but at least one other component with stable disease (SD); no component with PD. OR rate was presented as percentage of participants with BOR of CR or PR or MR.

Time frame:
First dose of study treatment (Day 1) up to maximum of approximately 25 months
Reported as:
Number · Percentage of Participants
TSC: OR Rate Based on Investigator Assessment
Percentage of ParticipantsTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
TSC: OR Rate Based on Investigator Assessment28.6 (12.5 to 52.8)
PrimaryPhase 2: Event Free Survival (EFS) Based on Investigator Assessment

EFS: time from date of randomization to the date of first documentation of any of the following events based on investigator assessment: objective PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.

Time frame:
From date of randomization up to objective PD, diagnosis of secondary malignancy or death, whichever occurred first (maximum of approximately 14 months)
Reported as:
Median · Months
Phase 2: Event Free Survival (EFS) Based on Investigator Assessment
MonthsPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Phase 2: Event Free Survival (EFS) Based on Investigator Assessment1.54 (1.41 to 4.24)4.4 (2.6 to NA)
Statistical analysis
  • Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ vs Phase 2: IRN + TMZ · Log Rank · p = 0.9621 · Hazard ratio (hr): 2.03 · 95% CI 0.902 to 4.572
SecondaryPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, and Maximum Grade 3 or 4 and 5 AEs by CTCAE v4.03

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Reported as:
Count of participants · Participants
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, and Maximum Grade 3 or 4 and 5 AEs by CTCAE v4.03
ParticipantsPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
Participants With Treatment-emergent AEs4666
Participants With Treatment-emergent SAEs2222
Participants With Treatment Related AEs4666
Participants With Treatment Related SAEs1122
Participants With Maximum Grade 3 or 4 AEs4466
Participants With Maximum Grade 5 AEs0000
SecondaryPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Hematology Parameters

Hematology parameters included activated partial thromboplastin time prolonged, anemia, hemoglobin increased, INR increased, lymphocyte count decreased and increased, neutrophil count decreased, platelet count decreased. Grades by CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe AE, Grade 4= life-threatening and, Grade 5= death related to AE; Grade 0= non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Only those parameters are reported which had at least 1 participant for any reporting group.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Reported as:
Count of participants · Participants
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Hematology Parameters
ParticipantsPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
Anemia — Grade 00110
Anemia — Grade 13230
Anemia — Grade 21312
Anemia — Grade 30014
Anemia — Grade 4NANANANA
Hemoglobin increased — Grade 04666
Hemoglobin increased — Grade 10000
Hemoglobin increased — Grade 20000
Hemoglobin increased — Grade 30000
Hemoglobin increased — Grade 4NANANANA
Lymphocyte count decreased — Grade 01100
Lymphocyte count decreased — Grade 10220
Lymphocyte count decreased — Grade 22120
Lymphocyte count decreased — Grade 31223
Lymphocyte count decreased — Grade 40003
Lymphocyte count increased — Grade 04665
Lymphocyte count increased — Grade 1NANANANA
Lymphocyte count increased — Grade 20000
Lymphocyte count increased — Grade 30001
Lymphocyte count increased — Grade 4NANANANA
Neutrophil count decreased — Grade 00000
Neutrophil count decreased — Grade 11000
Neutrophil count decreased — Grade 21310
Neutrophil count decreased — Grade 32032
Neutrophil count decreased — Grade 40324
Platelet count decreased — Grade 01210
Platelet count decreased — Grade 11240
Platelet count decreased — Grade 20101
Platelet count decreased — Grade 31001
Platelet count decreased — Grade 41114
SecondaryPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters

Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, GGT increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and, Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Only those parameters are reported which had at least 1 participant for any reporting group.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
Reported as:
Count of participants · Participants
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters
ParticipantsPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
Alanine aminotransferase increased — Grade 02343
Alanine aminotransferase increased — Grade 11223
Alanine aminotransferase increased — Grade 21100
Alanine aminotransferase increased — Grade 30000
Alanine aminotransferase increased — Grade 40000
Alkaline phosphatase increased — Grade 03563
Alkaline phosphatase increased — Grade 10103
Alkaline phosphatase increased — Grade 21000
Alkaline phosphatase increased — Grade 30000
Alkaline phosphatase increased — Grade 40000
Aspartate aminotransferase increased — Grade 00444
Aspartate aminotransferase increased — Grade 14222
Aspartate aminotransferase increased — Grade 20000
Aspartate aminotransferase increased — Grade 30000
Aspartate aminotransferase increased — Grade 40000
Blood bilirubin increased — Grade 04665
Blood bilirubin increased — Grade 10000
Blood bilirubin increased — Grade 20001
Blood bilirubin increased — Grade 30000
Blood bilirubin increased — Grade 40000
Creatinine increased — Grade 00002
Creatinine increased — Grade 14664
Creatinine increased — Grade 20000
Creatinine increased — Grade 30000
Creatinine increased — Grade 40000
Hypercalcemia — Grade 04665
Hypercalcemia — Grade 10001
Hypercalcemia — Grade 20000
Hypercalcemia — Grade 30000
Hypercalcemia — Grade 40000
Hyperglycemia — Grade 04666
Hyperglycemia — Grade 10000
Hyperglycemia — Grade 20000
Hyperglycemia — Grade 30000
Hyperglycemia — Grade 40000
Hyperkalemia — Grade 04666
Hyperkalemia — Grade 10000
Hyperkalemia — Grade 20000
Hyperkalemia — Grade 30000
Hyperkalemia — Grade 40000
Hypermagnesemia — Grade 04454
Hypermagnesemia — Grade 10212
Hypermagnesemia — Grade 2NANANANA
Hypermagnesemia — Grade 30000
Hypermagnesemia — Grade 40000
Hypernatremia — Grade 04566
Hypernatremia — Grade 10100
Hypernatremia — Grade 20000
Hypernatremia — Grade 30000
Hypernatremia — Grade 40000
Hypoalbuminemia — Grade 03441
Hypoalbuminemia — Grade 11224
Hypoalbuminemia — Grade 20000
Hypoalbuminemia — Grade 30001
Hypoalbuminemia — Grade 4NANANANA
Hypocalcemia — Grade 03455
Hypocalcemia — Grade 11211
Hypocalcemia — Grade 20000
Hypocalcemia — Grade 30000
Hypocalcemia — Grade 40000
Hypoglycemia — Grade 04556
Hypoglycemia — Grade 10110
Hypoglycemia — Grade 20000
Hypoglycemia — Grade 30000
Hypoglycemia — Grade 40000
Hypokalemia — Grade 03464
Hypokalemia — Grade 1NANANANA
Hypokalemia — Grade 21202
Hypokalemia — Grade 30000
Hypokalemia — Grade 40000
Hypomagnesemia — Grade 04664
Hypomagnesemia — Grade 10002
Hypomagnesemia — Grade 20000
Hypomagnesemia — Grade 30000
Hypomagnesemia — Grade 40000
Hyponatremia — Grade 03663
Hyponatremia — Grade 11003
Hyponatremia — Grade 2NANANANA
Hyponatremia — Grade 30000
Hyponatremia — Grade 40000
Hypophosphatemia — Grade 04554
Hypophosphatemia — Grade 10011
Hypophosphatemia — Grade 20101
Hypophosphatemia — Grade 30000
Hypophosphatemia — Grade 40000
SecondaryPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG Parameters

ECG parameters included RR interval, PR interval, QRS complex, QT interval, QTc interval, QTcB interval and QTcF interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters are recorded.

Time frame:
Baseline (pre-treatment) up to Cycle 3 (63 days)
Reported as:
Count of participants · Participants
Phase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG Parameters
ParticipantsPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
PR Interval (msec) Value >=3000000
PR Interval (msec) % Change>=25% and Baseline > 2000000
PR Interval (msec) % Change>=50% and Baseline <=2000000
QRS Interval (msec) Value >=2000000
QRS Interval (msec) %Change>=25% and Baseline >= 1000000
QRS Interval (msec) %Change>=50% and Baseline < 1000000
QT Interval (msec) Value <=4504666
QT Interval (msec) 450<Value<=4800000
QT Interval (msec) 480<Value<=5000000
QT Interval (msec) >5000000
QT Interval (msec) Change<=303545
QT Interval (msec) 30<Change<=600121
QT Interval (msec) Change>601000
QTcB (msec) Value<=4500442
QTcB (msec) 450<Value<=4804123
QTcB (msec) 480<Value<=5000000
QTcB (msec) Value>5000001
QTcB (msec) Change<=303356
QTcB (msec) 30<Change<=601110
QTcB (msec) Change>600000
QTcF (msec) Value<=4504564
QTcF (msec) 450<Value<=4800001
QTcF (msec) 480<Value<=5000001
QTcF (msec) Value>5000000
QTcF (msec) Change<=302356
QTcF (msec) 30<Change<=602110
QTcF (msec) Change>600000
SecondaryPhase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure

Blood pressure evaluation included SBP and DBP. SBP and DBP were measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.

Time frame:
Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
Reported as:
Mean · millimeters of mercury
Phase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure
millimeters of mercuryPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
SBP-21.3 ± 9.88-10.0 ± 14.729.0 ± 21.64-5.0 ± 18.69
DBP-7.0 ± 10.980.3 ± 15.83-10.3 ± 15.491.2 ± 15.66
SecondaryPhase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate

Pulse rate was measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.

Time frame:
Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
Reported as:
Mean · Beats per minute
Phase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate
Beats per minutePhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Pulse Rate8.5 ± 33.8720.0 ± 30.1912.7 ± 21.763.2 ± 42.97
SecondaryPhase 1: Maximum Plasma Concentration (Cmax) at Steady-State of Palbociclib, TMZ, IRN, SN-38, CTX and TOPO

Cmax was observed directly from data. Active metabolite of IRN is 7-Ethyl-10-hydroxycamptothecin (SN-38). In this outcome measure, Cmax was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

Time frame:
Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Phase 1: Maximum Plasma Concentration (Cmax) at Steady-State of Palbociclib, TMZ, IRN, SN-38, CTX and TOPO
nanogram per milliliter (ng/mL)Palbociclib 55 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TMZ + IRN (Pooled)Palbociclib 95 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TOPO + CTX (Pooled)TSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Palbociclib80.44 ± 21113.2 ± 49127.9 ± 4491.45 ± 5881.31 ± 94
IRN629.3 ± 10595.5 ± 411033 ± 197——
SN-387.386 ± 1038.746 ± 7611.32 ± 69——
TMZ3930 ± 553960 ± 634404 ± 67——
TOPO———25.52 ± 7722.68 ± 57
CTX———14810 ± 4015510 ± 51
SecondaryPhase 1: Time to Reach Cmax (Tmax) of Palbociclib, TMZ, IRN SN-38, CTX and TOPO

Tmax was defined as time for Cmax. Active metabolite of IRN is SN-38. In this outcome measure, Tmax was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI. As pre-specified in protocol, time points in time frame could have a window of +/- 20% of the sampling time.

Time frame:
Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Reported as:
Median · Hours
Phase 1: Time to Reach Cmax (Tmax) of Palbociclib, TMZ, IRN SN-38, CTX and TOPO
HoursPalbociclib 55 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TMZ + IRN (Pooled)Palbociclib 95 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TOPO + CTX (Pooled)TSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Palbociclib6.03 (2.02 to 6.08)4.17 (1.85 to 6.47)5.02 (2.07 to 8.05)4.05 (1.97 to 24.0)4.0 (2.05 to 24.0)
IRN1.53 (1.5 to 1.62)1.58 (0.017 to 2.0)1.61 (1.53 to 1.78)——
SN-382.64 (1.53 to 4.0)1.58 (0.017 to 6.02)1.61 (1.53 to 1.78)——
TMZ1.12 (0.983 to 4.03)1.63 (0.95 to 4.08)2.84 (0.783 to 8.05)——
TOPO———0.567 (0.45 to 3.3)0.533 (0.5 to 0.783)
CTX———0.617 (0.0 to 2.68)0.842 (0.533 to 1.98)
SecondaryPhase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) of Palbociclib, TMZ, IRN SN-38, CTX and TOPO

Area under the concentration-time profile from time zero to the time tau. AUCtau was determined using the linear/log trapezoidal method. Active metabolite of IRN is SN-38. In this outcome measure, AUCtau was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

Time frame:
Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Reported as:
Geometric mean · Hours*Nanogram per milliliter (hr*ng/mL)
Phase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) of Palbociclib, TMZ, IRN SN-38, CTX and TOPO
Hours*Nanogram per milliliter (hr*ng/mL)Palbociclib 55 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TMZ + IRN (Pooled)Palbociclib 95 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TOPO + CTX (Pooled)TSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Palbociclib1161 ± 71538 ± 492082 ± 381290 ± 591155 ± 102
IRN3394 ± 282781 ± 444917 ± 111——
SN-3869.46 ± 11278.2 ± 13098.28 ± 31——
TMZ18990 ± 2916970 ± 5826350 ± 40——
TOPO———49.27 ± 5240.25 ± 55
CTX———66260 ± 2665340 ± 34
SecondaryPhase 1: Pre-dose Plasma Concentration (Ctrough) at Steady-State of Palbociclib, TMZ, IRN SN-38, CTX and TOPO

Ctrough was defined as pre-dose plasma concentration during multiple dosing and observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Ctrough was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D.

Time frame:
Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5 or TMZ IV- PRD C1D5, C2D5
Reported as:
Mean · ng/mL
Phase 1: Pre-dose Plasma Concentration (Ctrough) at Steady-State of Palbociclib, TMZ, IRN SN-38, CTX and TOPO
ng/mLPalbociclib 55 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TMZ + IRN (Pooled)Palbociclib 95 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TOPO + CTX (Pooled)TSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Palbociclib30.42 ± 736.01 ± 5044.75 ± 5423.98 ± 8120.88 ± 76
IRN18.1 ± 10215.62 ± 5616.21 ± 77——
SN-382.125 ± 3.04582.063 ± 2.7311.123 ± 1.0186——
TMZ0.0 ± 0.00.0 ± 0.02.45 ± 6.0012——
TOPO———0.0 ± 0.00.0 ± 0.0
CTX———232.8 ± 217142.4 ± 136
SecondaryPhase 1: Clearance of Palbociclib, TMZ, IRN SN-38, CTX and TOPO

Clearance of a drug is a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Active metabolite of IRN is SN-38. In this outcome measure, clearance was reported for Phase 1: based on dose-level and combination, dose escalation and dose expansion cohorts were combined/pooled, wherever applicable and Phase 1: TSC. For IV administration CL/F was reported while for oral CL was reported. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

Time frame:
Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
Reported as:
Geometric mean · liter per hour (L/h)
Phase 1: Clearance of Palbociclib, TMZ, IRN SN-38, CTX and TOPO
liter per hour (L/h)Palbociclib 55 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TMZ + IRN (Pooled)Palbociclib 95 mg/m^2 + TMZ + IRNPalbociclib 75 mg/m^2 + TOPO + CTX (Pooled)TSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Palbociclib62.07 ± 4459.87 ± 8863.47 ± 5672.41 ± 5952.69 ± 83
IRN22.18 ± 2922.62 ± 5513.81 ± 83——
TMZ (Oral)7.884 ± 5111.01 ± 846.459 ± 60——
TMZ (IV)—2.935 ± 532.38——
TOPO———18.35 ± 6815.63 ± 59
CTX———4.731 ± 433.098 ± 16
SecondaryPhase 1, Dose Escalation/Dose Determination Cohorts: OR Rate Based on Investigator Assessment

OR: BOR of confirmed CR or PR per RECIST v1.1 \[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm), no new lesion;PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\]or RANO for central nervous system malignancies\[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value, no new lesion\]; INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. OR rate: percentage of participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.

Time frame:
First dose of study treatment (Day 1) up to maximum of approximately 25 months
Reported as:
Number · Percentage of Participants
Phase 1, Dose Escalation/Dose Determination Cohorts: OR Rate Based on Investigator Assessment
Percentage of ParticipantsPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Escalation/Dose Determination Cohorts: OR Rate Based on Investigator Assessment0 (0.0 to 49.0)0 (0.0 to 39.0)0 (0.0 to 39.0)16.7 (3.0 to 56.4)
SecondaryPhase 1, Dose Escalation/Dose Determination Cohorts: Duration of Response (DOR) Based on Investigator Assessment

DOR was defined for participants with OR:time from the date of first documentation of OR to the date of first documentation of PD or death due to any cause. OR: BOR of confirmed CR or PR per RECIST v1.1\[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size(short axis\<10 mm),no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\] or RANO for central nervous system malignancies \[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters of target lesions, compared to baseline value, no new lesion\]; INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. OR rate: % participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.

Time frame:
From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)
Reported as:
Median · Months
Phase 1, Dose Escalation/Dose Determination Cohorts: Duration of Response (DOR) Based on Investigator Assessment
MonthsPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Escalation/Dose Determination Cohorts: Duration of Response (DOR) Based on Investigator Assessment———NA
SecondaryPhase 1, Dose Expansion Cohorts and TSC: DOR Based on Investigator Assessment

DOR for participants with OR: time from the date of first documentation of OR to the date of first documentation of PD or death due to any cause. OR: BOR of confirmed CR or PR per RECIST v1.1 \[CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion\] or RANO for central nervous system malignancies \[CR: disappearance of all target lesions, no new lesion; PR:\>=50% decrease in sum of products of 2 perpendicular diameters INRC for neuroblastoma also included MR \[per protocol different criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow\]. of target lesions, compared to baseline value, no new lesion\]; OR rate: % participants with BOR of CR or PR per RECIST or RANO; BOR of CR or PR or MR per INRC for neuroblastoma.

Time frame:
From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)
Reported as:
Median · Months
Phase 1, Dose Expansion Cohorts and TSC: DOR Based on Investigator Assessment
MonthsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTumor-Specific Cohort (TSC): Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Expansion Cohorts and TSC: DOR Based on Investigator AssessmentNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPhase 1, Dose Expansion Cohorts and TSC: Progression-Free Survival (PFS) Based on Investigator Assessment

PFS: time from date of first dose of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever occurred first. Per RECIST, PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Per RANO, PD: \>=25% increase in the product of perpendicular diameters of any target lesion, taking as reference the smallest product; the appearance of one or more new lesions, worsening neurologic status not explained by causes unrelated to tumor progression; any increase in tumor cross-sectional area (tumor volume). Per INRC for neuroblastoma as specified in protocol different PD criteria for following components: soft tissue at primary site, metastatic soft tissue and bone sites, and bone marrow; overall PD was when any component fulfilled criteria of PD. Kaplan-Meier method was used for evaluation.

Time frame:
First dose of study treatment (Day 1) up to objective PD or death due to any cause, whichever occurred first (maximum of approximately 25 months)
Reported as:
Median · Months
Phase 1, Dose Expansion Cohorts and TSC: Progression-Free Survival (PFS) Based on Investigator Assessment
MonthsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTumor-Specific Cohort (TSC): Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Expansion Cohorts and TSC: Progression-Free Survival (PFS) Based on Investigator Assessment1.54 (1.41 to 2.92)4.04 (1.25 to 8.44)1.97 (1.08 to NA)
SecondaryPhase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS)

OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.

Time frame:
First dose of study treatment (Day 1) up to death due to any cause (maximum of approximately 25 months)
Reported as:
Median · Months
Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS)
MonthsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTumor-Specific Cohort (TSC): Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS)7.62 (4.27 to 14.59)7.46 (4.6 to 8.64)NA (NA to NA)
SecondaryPhase 2: Event-Free Survival (EFS) Based on Blinded Independent Review Committee (BIRC) Assessment

EFS: time from date of randomization to the date of first documentation of any of the following events based on investigator assessment: objective PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.

Time frame:
First date of randomization to the date of first objective PD, diagnosis of secondary malignancy, death due to any cause (maximum of approximately 14 months)
Reported as:
Median · Months
Phase 2: Event-Free Survival (EFS) Based on Blinded Independent Review Committee (BIRC) Assessment
MonthsPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Phase 2: Event-Free Survival (EFS) Based on Blinded Independent Review Committee (BIRC) Assessment1.54 (1.35 to 3.22)4.14 (1.38 to 9.13)
Statistical analysis
  • Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ vs Phase 2: IRN + TMZ · Log Rank · p = 0.8768 · Hazard ratio (hr): 1.54 · 95% CI 0.743 to 3.201Hazard ratio was based on Cox proportional hazards model.
SecondaryPhase 2: OR Rate Based on Investigator Assessment

OR: BOR of CR or PR per RECIST v1.1. CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion. OR rate was percentage of participants with BOR of CR or PR.

Time frame:
First dose of study treatment (Day 1) up to maximum of approximately 14 months
Reported as:
Number · Percentage of Participants
Phase 2: OR Rate Based on Investigator Assessment
Percentage of ParticipantsPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Phase 2: OR Rate Based on Investigator Assessment14.3 (6.3 to 29.4)15.8 (5.5 to 37.6)
Statistical analysis
  • Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ vs Phase 2: IRN + TMZ · Cochran-Mantel-Haenszel · p = 0.5829 · Odds ratio (or): 0.882 · 95% CI 0.151 to 6.350
SecondaryPhase 2: Comparison of Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Assessment With Magnetic Resonance Imaging (MRI)/ Computed Tomography (CT) Assessment for OR

CR or PR per RECIST v1.1. CR: complete disappearance of all target lesions except for nodal disease. All target nodes must decrease to normal size (short axis\<10 mm), no new lesion; PR:\>=30% decrease under baseline of sum of diameters of all target measurable lesions, no new lesion. PD per RECIST v.1.1 (including PD without achieving a response or recurrence following a response), diagnosis of secondary malignancy, death due to any cause. PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD= stable disease, NE= Not Evaluable.

Time frame:
Cycle 4
Reported as:
Count of participants · Participants
Phase 2: Comparison of Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Assessment With Magnetic Resonance Imaging (MRI)/ Computed Tomography (CT) Assessment for OR
ParticipantsPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
CR per FDG-PET00
CR per MRI/CT00
PR per FDG-PET23
PR per MRI/CT12
PD per FDG-PET33
PD per MRI/CT11
SD per FDG-PET30
SD per MRI/CT65
NE per FDG-PET02
NE per MRI/CT00
SecondaryPhase 2: PFS Based on Investigator Assessment

PFS: time from date of first dose of study treatment to the date of the first documentation of PD or death due to any cause. Per RECIST v1.1, PD: 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Kaplan-Meier method was used for evaluation.

Time frame:
First dose of study treatment (Day 1) up to PD or death due to any cause, whichever occurred (maximum of approximately 14 months)
Reported as:
Median · Months
Phase 2: PFS Based on Investigator Assessment
MonthsPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Phase 2: PFS Based on Investigator Assessment1.54 (1.41 to 4.24)4.4 (2.6 to NA)
Statistical analysis
  • Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ vs Phase 2: IRN + TMZ · Log Rank · p = 0.9621 · Hazard ratio (hr): 2.03 · 95% CI 0.902 to 4.572Hazard was ratio based on Cox proportional hazards model.
SecondaryPhase 2: OS

OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.

Time frame:
First dose of study treatment (Day 1) up to date of death due to any cause (maximum of approximately 76 months)
Reported as:
Median · Months
Phase 2: OS
MonthsPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Phase 2: OS10.64 (8.44 to 20.83)11.43 (7.46 to 19.02)
Statistical analysis
  • Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ vs Phase 2: IRN + TMZ · Hazard ratio (hr): 0.98 · 95% CI 0.489 to 1.960Hazard ratio was based on Cox proportional hazards model.
SecondaryPhase 2: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs: AEs that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect or other important medical event. Treatment-emergent AEs: AEs that occurred on or after the first dose of study treatment and up to 35 days after last dose of study treatment. AEs related to study drug as judged by the investigator were considered as treatment-related TEAEs. Severity of AEs were graded according to CTCAE version 4.03 as: Grade 3= severe, Grade 4= life threatening, and Grade 5= death related to AE.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 9.5 months)
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5
ParticipantsPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Participants With Treatment emergent AEs3820
Participants With Treatment -emergent SAEs154
Participants With Treatment Related AEs3619
Participants With Treatment Related SAEs73
Participants With Maximum Grade 3 or 4 AEs3417
Participants With Maximum Grade 5 AEs10
SecondaryPhase 2: Cmax at Steady-State of Palbociclib, TMZ, IRN and SN-38

Cmax was observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Cmax was reported only for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

Time frame:
Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Reported as:
Geometric mean · ng/mL
Phase 2: Cmax at Steady-State of Palbociclib, TMZ, IRN and SN-38
ng/mLPalbociclib 75 mg/m^2 + IRN + TMZ
Palbociclib114.4 ± 49
IRN709.9 ± 72
SN-388.527 ± 61
TMZ3457 ± 75
SecondaryPhase 2: Tmax of Palbociclib, TMZ, IRN and SN-38

Tmax was defined as time for Cmax. Active metabolite of IRN is SN-38. In this outcome measure, Tmax was reported only for Phase 2: reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

Time frame:
Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
Reported as:
Median · Hours
Phase 2: Tmax of Palbociclib, TMZ, IRN and SN-38
HoursPalbociclib 75 mg/m^2 + IRN + TMZ
Palbociclib4.0 (1.68 to 8.0)
IRN1.57 (1.42 to 4.02)
SN-381.58 (1.42 to 6.83)
TMZ1.11 (0.667 to 4.13)
SecondaryPhase 2: AUCtau,ss of Palbociclib, TMZ, IRN and SN-38

Area under the concentration-time profile from time zero to the time tau. AUCtau was determined using the linear/log trapezoidal method. Active metabolite of IRN is SN-38. In this outcome measure, AUCtau was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

Time frame:
Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
Reported as:
Geometric mean · hr*ng/mL
Phase 2: AUCtau,ss of Palbociclib, TMZ, IRN and SN-38
hr*ng/mLPalbociclib 75 mg/m^2 + IRN + TMZ
Palbociclib1525 ± 38
IRN2773 ± 28
SN-3869.83 ± 77
TMZ19470 ± 31
SecondaryPhase 2: Ctrough at Steady-State of Palbociclib, TMZ, IRN and SN-38

Ctrough was defined as pre-dose plasma concentration during multiple dosing and observed directly from data. Active metabolite of IRN is SN-38. In this outcome measure, Ctrough was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D.

Time frame:
Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38 : PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5; or TMZ IV- PRD C1D5, C2D5
Reported as:
Mean · ng/mL
Phase 2: Ctrough at Steady-State of Palbociclib, TMZ, IRN and SN-38
ng/mLPalbociclib 75 mg/m^2 + IRN + TMZ
Palbociclib26.09 ± 80
IRN14.25 ± 57
SN-381.434 ± 1.91
TMZ0.0 ± 0.0
SecondaryPhase 2: Clearance of Palbociclib, TMZ, IRN and SN-38

Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. Active metabolite of IRN is SN-38. In this outcome measure, clearance was reported for Phase 2 reporting group Palbociclib 75 mg/m\^2 + IRN + TMZ and not for reporting group IRN + TMZ, as pre-specified objective was to evaluate PK data of palbociclib, TMZ and IRN when given in combination. For IV administration CL/F was reported while for oral administration CL was reported. In below time frame few abbreviations have been used, where hour = hr, pre-dose = PRD, Cycle = C, Day = D, post-dose = PTD and post-infusion = PTI.

Time frame:
Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
Reported as:
Geometric mean · L/h
Phase 2: Clearance of Palbociclib, TMZ, IRN and SN-38
L/hPalbociclib 75 mg/m^2 + IRN + TMZ
Palbociclib63.65 ± 53
IRN23.43 ± 45
TMZ (IV)6.843 ± 49
TMZ (Oral)4.97
SecondaryPhase 2: Change From Baseline of Patient Reported Outcomes (PROMIS) Parent Proxy Profile v2.0 - Profile-25 Scale Score for Age >=5 to <=17 Years at Cycles 2 and 4

PROMIS Parent Proxy Profile V2.0 - Profile-25 instrument in this outcome measure was intended for parents serving as proxy reporters for their child (youth ages 5-17). The Profile-25 was a collection of short forms containing 4 items from six PROMIS domains (depressive symptoms, anxiety, physical function-mobility, pain interference, fatigue, and peer relationships with scores ranged from 20 to 80; where 20 = better health and 80 = worse health and for peer relationship 80 to 20; where 80 = better health and 20 = worse health along with a single item on pain intensity with 11 levels of responses from 0 (no pain) to 10 (worst pain you can think of).

Time frame:
Baseline, Cycles 2 and 4
Reported as:
Mean · Scores on a Scale
Phase 2: Change From Baseline of Patient Reported Outcomes (PROMIS) Parent Proxy Profile v2.0 - Profile-25 Scale Score for Age >=5 to <=17 Years at Cycles 2 and 4
Scores on a ScalePhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Anxiety Raw Summed Score Cycle 2-0.2 ± 3.19-3.3 ± 3.77
Anxiety Raw Summed Score Cycle 4-1.0 ± 2.58-4.0 ± 3.61
Depressive Symptoms Raw Summed Score Cycle 20.0 ± 2.0-1.3 ± 3.5
Depressive Symptoms Raw Summed Score Cycle 40.0 ± 2.45-1.0 ± 5.0
Fatigue Raw Summed Score Cycle 20.2 ± 4.12-2.8 ± 2.22
Fatigue Raw Summed Score Cycle 42.3 ± 4.27-3.0 ± 2.65
Pain Intensity Raw Summed Score Cycle 2-0.5 ± 3.51-3.8 ± 2.87
Pain Intensity Raw Summed Score Cycle 42.0 ± 4.16-3.3 ± 3.06
Pain Interference Raw Summed Score Cycle 2-2.5 ± 5.68-6.0 ± 5.48
Pain Interference Raw Summed Score Cycle 40.5 ± 8.74-4.7 ± 2.89
Peer Relationships Raw Summed Score Cycle 2-1.0 ± 4.11.5 ± 4.43
Peer Relationships Raw Summed Score Cycle 4-1.0 ± 3.740.3 ± 7.51
Physical Function Mobility Raw Summed Score Cycle 2-1.8 ± 1.834.5 ± 2.65
Physical Function Mobility Raw Summed Score Cycle 4-2.3 ± 3.777.3 ± 3.06
SecondaryPhase 2: Change From Baseline of PROMIS Pediatric Profile v2.0 - Profile-25 Scale Score for Age >=8 to <=17 Years at Cycles 2 and 4

PROMIS Parent Proxy Profile V2.0 - Profile-25 instrument in this outcome measure was intended for parents serving as proxy reporters for their child (youth ages 5-17). The Profile-25 was a collection of short forms containing 4 items from six PROMIS domains (depressive symptoms, anxiety, physical function-mobility, pain interference, fatigue, and peer relationships with each item having 5 levels of responses (1=Never, 2=Almost never, 3=Sometimes, 4=Often, and 5=Almost always) along with a single item on pain intensity with 11 levels of responses from 0 (No pain) to 10 (Worst pain you can think of).

Time frame:
Baseline, Cycles 2 and 4
Reported as:
Mean · Scores on a Scale
Phase 2: Change From Baseline of PROMIS Pediatric Profile v2.0 - Profile-25 Scale Score for Age >=8 to <=17 Years at Cycles 2 and 4
Scores on a ScalePhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Anxiety Raw Summed Score Cycle 20.2 ± 2.71-1.5 ± 4.09
Anxiety Raw Summed Score Cycle 40.8 ± 2.5-1.8 ± 2.17
Depressive Symptoms Raw Summed Score Cycle 2-0.8 ± 1.72-1.8 ± 1.92
Depressive Symptoms Raw Summed Score Cycle 41.0 ± 2.94-2.4 ± 2.07
Fatigue Raw Summed Score Cycle 20.3 ± 3.01-1.5 ± 0.84
Fatigue Raw Summed Score Cycle 42.8 ± 2.63-1.8 ± 0.84
Pain Intensity Raw Summed Score Cycle 2-0.3 ± 2.94-2.5 ± 3.83
Pain Intensity Raw Summed Score Cycle 41.8 ± 2.22-2.6 ± 3.65
Pain Interference Raw Summed Score Cycle 21.5 ± 6.12-3.7 ± 7.99
Pain Interference Raw Summed Score Cycle 45.8 ± 4.57-4.8 ± 5.59
Peer Relationships Raw Summed Score Cycle 21.5 ± 1.521.8 ± 3.25
Peer Relationships Raw Summed Score Cycle 41.0 ± 3.741.0 ± 1.41
Physical Function Mobility Raw Summed Score Cycle 2-1.2 ± 0.981.7 ± 2.58
Physical Function Mobility Raw Summed Score Cycle 4-3.3 ± 2.871.8 ± 3.7
SecondaryPhase 2: Change From Baseline of PROMIS-29 Profile v2.1 Scale Score for Age >=18 Years at Cycles 2 and 4

PROMIS Profile-29 had eight domains (ability to participate in social roles, anxiety, depression, fatigue, pain Intensity, pain Interference, physical function, sleep disturbance). There were four items for each domain except pain intensity which had only 1 item. All items (except pain intensity) had a score of 1 to 5, when scores from each item was summed, it resulted to score ranged from 4 to 20, (except for pain intensity, where it is 1 to 10, highest score = worst pain), where for physical function highest score = without any difficulty and lowest score = unable to do; anxiety, depression, fatigue highest score = always and lowest score = never; sleep disturbance highest score = not at all, lowest score = very much; ability to participate in social roles and activities (trouble) highest score = never and lowest score = always; pain interference highest score = very much and lowest score = not at all.

Time frame:
Baseline, Cycles 2 and 4
Reported as:
Mean · Scores on a Scale
Phase 2: Change From Baseline of PROMIS-29 Profile v2.1 Scale Score for Age >=18 Years at Cycles 2 and 4
Scores on a ScalePhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Ability to Participate in Social Roles Raw Summed Score Cycle 23.0 ± 4.24-2.0
Ability to Participate in Social Roles Raw Summed Score Cycle 4-3.0-2.0
Anxiety Raw Summed Score Cycle 2-2.0 ± 1.410.0
Anxiety Raw Summed Score Cycle 4-3.00.0
Depression Raw Summed Score Cycle 2-1.5 ± 2.120.0
Depression Raw Summed Score Cycle 40.02.0
Fatigue Raw Summed Score Cycle 2-5.5 ± 4.955.0
Fatigue Raw Summed Score Cycle 4-3.08.0
Pain Intensity Raw Summed Score Cycle 2-0.5 ± 2.12-1.0
Pain Intensity Raw Summed Score Cycle 4-1.0-1.0
Pain Interference Raw Summed Score Cycle 2-1.0 ± 1.411.0
Pain Interference Raw Summed Score Cycle 40.01.0
Physical Function Raw Summed Score Cycle 21.0 ± 1.41-8.0
Physical Function Raw Summed Score Cycle 4—-4.0
Sleep Disturbance Raw Summed Score Cycle 21.0 ± 1.412.0
Sleep Disturbance Raw Summed Score Cycle 4-4.03.0
SecondaryPhase 2: Average Days of Hospitalization

Hospitalization included planned and unplanned inpatient admissions regardless the reason.

Time frame:
First dose of study treatment (Day 1) up to maximum of approximately 25 months
Reported as:
Mean · Days
Phase 2: Average Days of Hospitalization
DaysPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Phase 2: Average Days of Hospitalization3.5 ± 6.8041.26 ± 0.525
Other pre-specifiedPhase 1 TSC: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters - Upto Study Completion Date

Clinical chemistry parameters included: alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hypercalcemia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia and hypophosphatemia. According to CTCAE version 4.03: Grade 1=mild, Grade 2=moderate, Grade 3=severe and Grade 4= life-threatening; Grade 0: non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 24.2 months)
Reported as:
Count of participants · Participants
Phase 1 TSC: Number of Participants With Maximum CTCAE Grade in Chemistry Parameters - Upto Study Completion Date
ParticipantsTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
Alanine aminotransferase increased — Grade 02
Alanine aminotransferase increased — Grade 14
Alanine aminotransferase increased — Grade 20
Alanine aminotransferase increased — Grade 31
Alanine aminotransferase increased — Grade 40
Alkaline phosphatase increased — Grade 05
Alkaline phosphatase increased — Grade 12
Alkaline phosphatase increased — Grade 20
Alkaline phosphatase increased — Grade 30
Alkaline phosphatase increased — Grade 40
Aspartate aminotransferase increased — Grade 01
Aspartate aminotransferase increased — Grade 15
Aspartate aminotransferase increased — Grade 21
Aspartate aminotransferase increased — Grade 30
Aspartate aminotransferase increased — Grade 40
Blood bilirubin increased — Grade 06
Blood bilirubin increased — Grade 11
Blood bilirubin increased — Grade 20
Blood bilirubin increased — Grade 30
Blood bilirubin increased — Grade 40
Creatinine increased — Grade 01
Creatinine increased — Grade 14
Creatinine increased — Grade 22
Creatinine increased — Grade 30
Creatinine increased — Grade 40
GGT increased — Grade 01
GGT increased — Grade 10
GGT increased — Grade 20
GGT increased — Grade 30
GGT increased — Grade 40
Hypercalcemia — Grade 07
Hypercalcemia — Grade 10
Hypercalcemia — Grade 20
Hypercalcemia — Grade 30
Hypercalcemia — Grade 40
Hyperglycemia — Grade 06
Hyperglycemia — Grade 11
Hyperglycemia — Grade 20
Hyperglycemia — Grade 30
Hyperglycemia — Grade 40
Hyperkalemia — Grade 06
Hyperkalemia — Grade 11
Hyperkalemia — Grade 20
Hyperkalemia — Grade 30
Hyperkalemia — Grade 40
Hypermagnesemia — Grade 03
Hypermagnesemia — Grade 13
Hypermagnesemia — Grade 2NA
Hypermagnesemia — Grade 30
Hypermagnesemia — Grade 41
Hypernatremia — Grade 07
Hypernatremia — Grade 10
Hypernatremia — Grade 20
Hypernatremia — Grade 30
Hypernatremia — Grade 40
Hypoalbuminemia — Grade 04
Hypoalbuminemia — Grade 12
Hypoalbuminemia — Grade 21
Hypoalbuminemia — Grade 30
Hypoalbuminemia — Grade 4NA
Hypocalcemia — Grade 03
Hypocalcemia — Grade 14
Hypocalcemia — Grade 20
Hypocalcemia — Grade 30
Hypocalcemia — Grade 40
Hypoglycemia — Grade 06
Hypoglycemia — Grade 10
Hypoglycemia — Grade 20
Hypoglycemia — Grade 30
Hypoglycemia — Grade 41
Hypokalemia — Grade 05
Hypokalemia — Grade 1NA
Hypokalemia — Grade 21
Hypokalemia — Grade 31
Hypokalemia — Grade 40
Hypomagnesemia — Grade 06
Hypomagnesemia — Grade 11
Hypomagnesemia — Grade 20
Hypomagnesemia — Grade 30
Hypomagnesemia — Grade 40
Hyponatremia — Grade 03
Hyponatremia — Grade 14
Hyponatremia — Grade 2NA
Hyponatremia — Grade 30
Hyponatremia — Grade 40
Hypophosphatemia — Grade 04
Hypophosphatemia — Grade 13
Hypophosphatemia — Grade 20
Hypophosphatemia — Grade 30
Hypophosphatemia — Grade 40
Other pre-specifiedPhase 1 TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG Parameters - Upto Study Completion Date

ECG parameters included PR interval, QRS interval, QT interval, Bazett's correction QT (QTcB) interval and Fridericia's correction (QTcF) interval. In this outcome measure number of participants with post-baseline values and with maximum change from baseline values in ECG parameters were recorded.

Time frame:
First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 24.2 months)
Reported as:
Count of participants · Participants
Phase 1 TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG Parameters - Upto Study Completion Date
ParticipantsTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
PR Interval (millisecond [msec]) Value greater than equal to (>=)3000
PR Interval (msec) %Change>=25% and Baseline > 2000
PR Interval (msec) %Change>=50% and Baseline <=2000
QRS Interval (msec) Value >=2000
QRS Interval (msec) %Change>=25% and Baseline >= 1001
QRS Interval (msec) %Change>=50% and Baseline < 1000
QT Interval (msec) Value less than equal to (<=)4507
QT Interval (msec) 450<Value<=4800
QT Interval (msec) 480<Value<=5000
QT Interval (msec) >5000
QT Interval (msec) Change<=303
QT Interval (msec) 30<Change<=601
QT Interval (msec) Change>600
QTcB (msec) Value<=4504
QTcB (msec) 450<Value<=4803
QTcB (msec) 480<Value<=5000
QTcB (msec) Value>5000
QTcB (msec) Change<=303
QTcB (msec) 30<Change<=601
QTcB (msec) Change>600
QTcF (msec) Value<=4507
QTcF (msec) 450<Value<=4800
QTcF (msec) 480<Value<=5000
QTcF (msec) Value>5000
QTcF (msec) Change<=302
QTcF (msec) 30<Change<=602
QTcF (msec) Change>600
Other pre-specifiedPhase 1 TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure (Upto Study Completion Date)

Blood pressure evaluation included systolic blood pressure (SBP) and diastolic blood pressure (DBP). SBP and DBP were measured in a supine position using an automated device preceded by at least 5 minutes of rest for the participant in a quiet setting without any distractions.

Time frame:
Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 24.2 months)
Reported as:
Mean · millimeters of mercury
Phase 1 TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood Pressure (Upto Study Completion Date)
millimeters of mercuryTSC: Palbociclib 75 mg/m^2 + TOPO + CTX
SBP5.4 ± 21.54
DBP-9.3 ± 11.71
Other pre-specifiedPhase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS) - Upto Study Completion Date

OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.

Time frame:
First dose of study treatment (Day 1) up to death due to any cause (maximum of approximately 26 months)
Reported as:
Median · Months
Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS) - Upto Study Completion Date
MonthsPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTumor-Specific Cohort (TSC): Palbociclib 75 mg/m^2 + TOPO + CTX
Phase 1, Dose Expansion Cohorts and TSC: Overall Survival (OS) - Upto Study Completion Date13.04 (4.67 to 25.3)8.54 (7.39 to 19.71)NA (NA to NA)
Other pre-specifiedPhase 2: OS - Upto Study Completion Date

OS: time from date of first dose of study treatment to the date of death due to any cause. Kaplan-Meier method was used for evaluation.

Time frame:
First dose of study treatment (Day 1) up to date of death due to any cause (maximum up to 76 months of treatment exposure)
Reported as:
Median · Months
Phase 2: OS - Upto Study Completion Date
MonthsPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Phase 2: OS - Upto Study Completion Date10.68 (8.44 to 20.9)11.43 (7.46 to 19.84)
Statistical analysis
  • Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ vs Phase 2: IRN + TMZ · Hazard ratio (hr): 0.94 · 95% CI 0.491 to 1.786Hazard ratio was based on Cox proportional hazards model.

Adverse events

Collected over Phase 1 and TSC: AEs and all-cause mortality: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 and 24.2 months respectively respectively); Phase 2: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 76 months); All-cause mortality: up to approximately 14 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRN3/6 (50%)2/6 (33.3%)6/6 (100%)
Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRN12/17 (70.6%)8/17 (47.1%)17/17 (100%)
Phase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRN2/4 (50%)2/4 (50%)4/4 (100%)
Phase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRN5/6 (83.3%)2/6 (33.3%)6/6 (100%)
Phase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX3/6 (50%)2/6 (33.3%)6/6 (100%)
Phase 1, Dose Escalation Cohort 2 + Dose Expansion: Palbociclib 75 mg/m^2 + TMZ + IRN15/23 (65.2%)10/23 (43.5%)23/23 (100%)
Phase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTX14/20 (70%)10/20 (50%)20/20 (100%)
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX2/7 (28.6%)4/7 (57.1%)7/7 (100%)
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ26/41 (63.4%)15/41 (36.6%)37/41 (90.2%)
Phase 2: IRN + TMZ15/21 (71.4%)4/21 (19%)20/21 (95.2%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 1, Dose Escalation Cohort 2 + Dose Expansion: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
Febrile neutropeniaBlood and lymphatic system disorders1/61/170/40/61/62/236/201/74/410/21
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/60/171/40/60/60/230/200/70/410/21
ShockVascular disorders0/60/171/40/60/60/230/200/70/410/21
Atrial fibrillationCardiac disorders1/60/170/40/60/61/230/200/70/410/21
Pericardial effusionCardiac disorders1/60/170/40/60/61/230/200/70/410/21
Chest painGeneral disorders1/60/170/40/60/61/230/200/70/410/21
Neutrophil count decreasedInvestigations0/60/170/41/60/60/230/200/70/411/21
Platelet count decreasedInvestigations0/60/170/41/61/60/230/201/70/410/21
AnaemiaBlood and lymphatic system disorders0/61/170/40/60/61/230/201/71/410/21
Suicidal ideationPsychiatric disorders0/60/170/40/60/60/231/201/70/410/21
Most frequent other events
Showing 10 of 153
Most frequent other events
EventPhase 1, Dose Escalation Cohort 2: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 1: Palbociclib 55 mg/m^2 + TMZ + IRNPhase 1, Dose Escalation Cohort 3: Palbociclib 95 mg/m^2 + TMZ + IRNPhase 1, Dose Determination Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 1, Dose Escalation Cohort 2 + Dose Expansion: Palbociclib 75 mg/m^2 + TMZ + IRNPhase 1, Dose Expansion Cohort: Palbociclib 75 mg/m^2 + TOPO + CTXTSC: Palbociclib 75 mg/m^2 + TOPO + CTXPhase 2: Palbociclib 75 mg/m^2 + IRN + TMZPhase 2: IRN + TMZ
AnaemiaBlood and lymphatic system disorders1/614/172/44/64/615/2319/207/711/416/21
DiarrhoeaGastrointestinal disorders5/613/174/44/62/618/235/205/712/419/21
VomitingGastrointestinal disorders3/612/174/43/61/615/2311/204/714/415/21
Neutrophil count decreasedInvestigations3/616/172/45/66/619/2316/205/718/418/21
Platelet count decreasedInvestigations0/612/171/44/66/612/2317/206/78/415/21
White blood cell count decreasedInvestigations1/613/172/44/65/614/2316/204/78/415/21
NauseaGastrointestinal disorders4/613/173/44/64/617/2314/205/711/414/21
Lymphocyte count decreasedInvestigations1/610/171/43/64/611/2314/203/75/410/21
Decreased appetiteMetabolism and nutrition disorders3/62/172/44/61/65/233/201/70/410/21
HeadacheNervous system disorders2/64/171/44/62/66/237/201/70/410/21

Baseline characteristics

Baseline data are reported for FAS. "Number(no.) Analyzed"=no. of participants(ppts) included in FAS for Phase(P)1, TSC, P2 independently. Per protocol, two ppts with recurrent/refractory neuroblastoma (NB)from P1 were counted toward additional 5 ppts enrolled in NB TSC, for a total of 7 ppts required for Stage 1. To provide complete FAS of each cohort, these ppts are included in "No. Analyzed" counts for both P1 \& TSC. To avoid duplicate counting, "N" for "P 1 + TSC" includes only unique ppts.

Age, Customized
Age, Customized(Participants)Phase 1 + TSCPhase 2Total
Phase 1, Dose Escalation Cohort 1 — <= 6 years0—0
Phase 1, Dose Escalation Cohort 1 — >6 to <12 years1—1
Phase 1, Dose Escalation Cohort 1 — >=12 to <18 Years2—2
Phase 1, Dose Escalation Cohort 1 — >=18 years1—1
Phase 1, Dose Escalation Cohort 2 — <= 6 years1—1
Phase 1, Dose Escalation Cohort 2 — >6 to <12 years1—1
Phase 1, Dose Escalation Cohort 2 — >=12 to <18 Years2—2
Phase 1, Dose Escalation Cohort 2 — >=18 years2—2
Phase 1, Dose Escalation Cohort 3 — <= 6 years1—1
Phase 1, Dose Escalation Cohort 3 — >6 to <12 years0—0
Phase 1, Dose Escalation Cohort 3 — >=12 to <18 Years4—4
Phase 1, Dose Escalation Cohort 3 — >=18 years1—1
Phase 1, Dose Expansion Cohort 4 — <= 6 years5—5
Phase 1, Dose Expansion Cohort 4 — >6 to <12 years3—3
Phase 1, Dose Expansion Cohort 4 — >=12 to <18 Years8—8
Phase 1, Dose Expansion Cohort 4 — >=18 years1—1
Phase 1, Dose Determination Cohort 5 — <= 6 years1—1
Phase 1, Dose Determination Cohort 5 — >6 to <12 years2—2
Phase 1, Dose Determination Cohort 5 — >=12 to <18 Years1—1
Phase 1, Dose Determination Cohort 5 — >=18 years2—2
Phase 1, Dose Expansion Cohort 6 — <= 6 years5—5
Phase 1, Dose Expansion Cohort 6 — >6 to <12 years6—6
Phase 1, Dose Expansion Cohort 6 — >=12 to <18 Years7—7
Phase 1, Dose Expansion Cohort 6 — >=18 years2—2
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — <= 6 years3—3
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — >6 to <12 years3—3
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — >=12 to <18 Years1—1
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — >=18 years0—0
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — <= 6 years—66
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — >6 to <12 years—77
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — >=12 to <18 Years—2323
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — >=18 years—66
Phase 2: IRN + TMZ — <= 6 years—11
Phase 2: IRN + TMZ — >6 to <12 years—44
Phase 2: IRN + TMZ — >=12 to <18 Years—1313
Phase 2: IRN + TMZ — >=18 years—33
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 + TSCPhase 2Total
Phase 1, Dose Escalation Cohort 1 — Female2—2
Phase 1, Dose Escalation Cohort 1 — Male2—2
Phase 1, Dose Escalation Cohort 2 — Female0—0
Phase 1, Dose Escalation Cohort 2 — Male6—6
Phase 1, Dose Escalation Cohort 3 — Female4—4
Phase 1, Dose Escalation Cohort 3 — Male2—2
Phase 1, Dose Expansion Cohort 4 — Female6—6
Phase 1, Dose Expansion Cohort 4 — Male11—11
Phase 1, Dose Determination Cohort 5 — Female3—3
Phase 1, Dose Determination Cohort 5 — Male3—3
Phase 1, Dose Expansion Cohort 6 — Female11—11
Phase 1, Dose Expansion Cohort 6 — Male9—9
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Female5—5
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Male2—2
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Female—99
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Male—3333
Phase 2: IRN+TMZ — Female—99
Phase 2: IRN+TMZ — Male—1212
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1 + TSCPhase 2Total
Phase 1, Dose Escalation Cohort 1 — Hispanic or Latino1—1
Phase 1, Dose Escalation Cohort 1 — Not Hispanic or Latino3—3
Phase 1, Dose Escalation Cohort 1 — Unknown or Not Reported0—0
Phase 1,Dose Escalation Cohort 2 — Hispanic or Latino1—1
Phase 1,Dose Escalation Cohort 2 — Not Hispanic or Latino5—5
Phase 1,Dose Escalation Cohort 2 — Unknown or Not Reported0—0
Phase 1, Dose Escalation Cohort 3 — Hispanic or Latino0—0
Phase 1, Dose Escalation Cohort 3 — Not Hispanic or Latino6—6
Phase 1, Dose Escalation Cohort 3 — Unknown or Not Reported0—0
Phase 1, Dose Expansion Cohort 4 — Hispanic or Latino5—5
Phase 1, Dose Expansion Cohort 4 — Not Hispanic or Latino11—11
Phase 1, Dose Expansion Cohort 4 — Unknown or Not Reported1—1
Phase 1, Dose Determination Cohort 5 — Hispanic or Latino1—1
Phase 1, Dose Determination Cohort 5 — Not Hispanic or Latino5—5
Phase 1, Dose Determination Cohort 5 — Unknown or Not Reported0—0
Phase 1, Dose Expansion Cohort 6 — Hispanic or Latino2—2
Phase 1, Dose Expansion Cohort 6 — Not Hispanic or Latino17—17
Phase 1, Dose Expansion Cohort 6 — Unknown or Not Reported1—1
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Hispanic or Latino1—1
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Not Hispanic or Latino6—6
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Unknown or Not Reported0—0
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Hispanic or Latino—55
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Not Hispanic or Latino—3232
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Unknown or Not Reported—55
Phase 2: IRN+TMZ — Hispanic or Latino—33
Phase 2: IRN+TMZ — Not Hispanic or Latino—1616
Phase 2: IRN+TMZ — Unknown or Not Reported—22
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1 + TSCPhase 2Total
Phase 1, Dose Escalation Cohort 1 — American Indian or Alaska Native0—0
Phase 1, Dose Escalation Cohort 1 — Asian0—0
Phase 1, Dose Escalation Cohort 1 — Native Hawaiian or Other Pacific Islander0—0
Phase 1, Dose Escalation Cohort 1 — Black or African American0—0
Phase 1, Dose Escalation Cohort 1 — White4—4
Phase 1, Dose Escalation Cohort 1 — More than one race0—0
Phase 1, Dose Escalation Cohort 1 — Unknown or Not Reported0—0
Phase 1, Dose Escalation Cohort 2 — American Indian or Alaska Native1—1
Phase 1, Dose Escalation Cohort 2 — Asian0—0
Phase 1, Dose Escalation Cohort 2 — Native Hawaiian or Other Pacific Islander0—0
Phase 1, Dose Escalation Cohort 2 — Black or African American2—2
Phase 1, Dose Escalation Cohort 2 — White3—3
Phase 1, Dose Escalation Cohort 2 — More than one race0—0
Phase 1, Dose Escalation Cohort 2 — Unknown or Not Reported0—0
Phase 1, Dose Escalation Cohort 3 — American Indian or Alaska Native0—0
Phase 1, Dose Escalation Cohort 3 — Asian0—0
Phase 1, Dose Escalation Cohort 3 — Native Hawaiian or Other Pacific Islander0—0
Phase 1, Dose Escalation Cohort 3 — Black or African American0—0
Phase 1, Dose Escalation Cohort 3 — White5—5
Phase 1, Dose Escalation Cohort 3 — More than one race1—1
Phase 1, Dose Escalation Cohort 3 — Unknown or Not Reported0—0
Phase 1, Dose Expansion Cohort 4 — American Indian or Alaska Native0—0
Phase 1, Dose Expansion Cohort 4 — Asian0—0
Phase 1, Dose Expansion Cohort 4 — Native Hawaiian or Other Pacific Islander0—0
Phase 1, Dose Expansion Cohort 4 — Black or African American0—0
Phase 1, Dose Expansion Cohort 4 — White9—9
Phase 1, Dose Expansion Cohort 4 — More than one race1—1
Phase 1, Dose Expansion Cohort 4 — Unknown or Not Reported7—7
Phase 1, Dose Determination Cohort 5 — American Indian or Alaska Native0—0
Phase 1, Dose Determination Cohort 5 — Asian0—0
Phase 1, Dose Determination Cohort 5 — Native Hawaiian or Other Pacific Islander0—0
Phase 1, Dose Determination Cohort 5 — Black or African American1—1
Phase 1, Dose Determination Cohort 5 — White4—4
Phase 1, Dose Determination Cohort 5 — More than one race1—1
Phase 1, Dose Determination Cohort 5 — Unknown or Not Reported0—0
Phase 1, Dose Expansion Cohort 6 — American Indian or Alaska Native0—0
Phase 1, Dose Expansion Cohort 6 — Asian0—0
Phase 1, Dose Expansion Cohort 6 — Native Hawaiian or Other Pacific Islander0—0
Phase 1, Dose Expansion Cohort 6 — Black or African American2—2
Phase 1, Dose Expansion Cohort 6 — White15—15
Phase 1, Dose Expansion Cohort 6 — More than one race0—0
Phase 1, Dose Expansion Cohort 6 — Unknown or Not Reported3—3
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — American Indian or Alaska Native0—0
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Asian1—1
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Native Hawaiian or Other Pacific Islander0—0
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Black or African American1—1
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — White4—4
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — More than one race1—1
TSC: Palbociclib 75 mg/m^2 + TOPO + CTX — Unknown or Not Reported0—0
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — American Indian or Alaska Native—00
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Asian—1212
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Native Hawaiian or Other Pacific Islander—00
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Black or African American—11
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — White—2323
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — More than one race—00
Phase 2: Palbociclib 75 mg/m^2 + IRN + TMZ — Unknown or Not Reported—66
Phase 2: IRN+TMZ — American Indian or Alaska Native—00
Phase 2: IRN+TMZ — Asian—66
Phase 2: IRN+TMZ — Native Hawaiian or Other Pacific Islander—00
Phase 2: IRN+TMZ — Black or African American—00
Phase 2: IRN+TMZ — White—1212
Phase 2: IRN+TMZ — More than one race—00
Phase 2: IRN+TMZ — Unknown or Not Reported—33
08

Study locations

84 sites
  • University of Alabama at Birmingham/Children's of Alabama
    Birmingham, Alabama 35233, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital Los Angeles Pharmacy Department
    Los Angeles, California 90027, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital and Research Center at Oakland
    Oakland, California 94609, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • UCSF Benioff Children's Hospital Investigational Pharmacy
    San Francisco, California 94158, United States
  • UCSF Medical Center
    San Francisco, California 94158, United States
  • University of California San Francisco,
    San Francisco, California 94158, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Children's National Hospital
    Washington D.C., District of Columbia 20010, United States
  • UF Health Shands Hospital
    Gainesville, Florida 32610, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32610, United States
  • Johns Hopkins All Children's Hospital
    St. Petersburg, Florida 33701, United States
  • Johns Hopkins All Children's Outpatient Care Center
    St. Petersburg, Florida 33701, United States
  • Johns Hopkins All Children's Hospital
    Tampa, Florida 33612, United States
  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital
    Atlanta, Georgia 30329, United States
  • Children's Healthcare of Atlanta at Scottish Rite
    Atlanta, Georgia 30342, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota Masonic Children's Hospital
    Minneapolis, Minnesota 55454, United States
  • University of Minnesota Medical Center, Fairview
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota/Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Robert Wood Johnson University Hospital
    New Brunswick, New Jersey 08901, United States
  • CINJ Research Pharmacy
    New Brunswick, New Jersey 08903, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
  • Morgan Stanley Children's Hospital of New York-Presbyetrian Hospital
    New York, New York 10032, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Cincinnati Children's Liberty Campus
    Liberty Township, Ohio 45044, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • OHSU- Research Pharmacy Services
    Portland, Oregon 97239, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Penn State Children's Hospital and Penn State Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Buerger Center for Advanced Pediatric Care
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • Cook Children's H/O Infusion Center
    Grapevine, Texas 76051, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Children's Medical Center Plano
    Plano, Texas 75024, United States
  • Intermountain - Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Primary Children's Hospital Outpatient Services
    Salt Lake City, Utah 84113, United States
  • Children's Hospital of The King's Daughters
    Norfolk, Virginia 23507, United States
  • Children's Hospital of Richmond at VCU
    Richmond, Virginia 23298, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Seattle Children's Investigational Drug Service, Pharmacy Department
    Seattle, Washington 98105, United States
  • Children's Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância
    Curitiba, Paraná 80250-060, Brazil
  • Hospital Pequeno Príncipe
    Curitiba, Paraná 80250-060, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90410000, Brazil
  • Fundação Pio XII - Hospital de Câncer de Barretos
    Barretos, São Paulo 14784400, Brazil
  • Instituto Nacional de Câncer - INCA
    Rio de Janeiro, 20230-130, Brazil
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • CHU Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
  • Detska nemocnice FN Brno
    Brno, Brno-město 613 00, Czechia
  • Fakultni nemocnice v Motole
    Prague, Praha 5 150 06, Czechia
  • Universitaetsklinikum Essen
    Essen, North Rhine-Westphalia 45122, Germany
  • Artemis hospital
    Gurugram, Haryana 122001, India
  • All India Institute of Medical Sciences
    New Delhi, National Capital Territory of Delhi 110029, India
  • Rajiv Gandhi Cancer Institute And Research Centre
    New Delhi, National Capital Territory of Delhi 110085, India
  • Instytut Matki i Dziecka
    Warsaw, Masovian Voivodeship 01-211, Poland
  • Detska fakultna nemocnica s poliklinikou Banska Bystrica
    Banská Bystrica, 974 09, Slovakia
  • Narodny ustav detskych chorob
    Bratislava, 83340, Slovakia
  • National Cancer Center
    Goyang-si, Kyǒnggi-do 10408, South Korea
  • Seoul National University Hospital
    Seoul, Seoul-teukbyeolsi [seoul] 03080, South Korea
  • Asan Medical Center
    Seoul, Seoul-teukbyeolsi [seoul] 05505, South Korea
  • Samsung Medical Center
    Seoul, Seoul-teukbyeolsi [seoul] 06351, South Korea
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [barcelona] 08035, Spain
  • Hospital Infantil Universitario Niño Jesús
    Madrid, Madrid, Comunidad de 28009, Spain
  • Sahlgrenska Universitetssjukhuset Östra
    Gothenburg, Västra Götalands LÄN [se-14] 416 50, Sweden
  • Ege Universitesi Hastanesi
    Izmir, İ̇zmir 35100, Turkey (Türkiye)
  • Hacettepe Universite Hastaneleri
    Ankara, 06100, Turkey (Türkiye)
  • University College London Hospital, NHS Foundation Trust
    London, NW1 2PG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Aug 2024, 63 months.

Results were first posted in Oct 2026, 2 years 1 month after primary completion.

Of 39 phase 2 interventional studies under Sarcoma, Ewing, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 92. This study's 63 months is above that.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2025 → Aug 2025, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2018
First posted
Oct 17, 2018
StartActual
May 24, 2019
Primary completionActual
Aug 26, 2024
CompletionActual
Aug 6, 2025was Oct 2025
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 7, 2026
Results
Results posted
posted Oct 7, 2026
Sites
22 sites added, 39 sites removed; no longer in France
Show 22 added (10 United States, 4 Brazil, 2 India, 1 Czechia, 1 Germany, 1 Poland, 1 Slovakia, 1 Spain, 1 Turkey (Türkiye))
  • Children's Hospital Los Angeles Pharmacy Department · Los Angeles, United States
  • UCSF Benioff Children's Hospital Investigational Pharmacy · San Francisco, United States
  • Children's National Hospital · Washington D.C., United States
  • Johns Hopkins All Children's Hospital · St. Petersburg, United States
  • Johns Hopkins All Children's Outpatient Care Center · St. Petersburg, United States
  • Children's Healthcare of Atlanta at Arthur M. Blank Hospital · Atlanta, United States
  • Washington University School of Medicine · St Louis, United States
  • CINJ Research Pharmacy · New Brunswick, United States
  • OHSU- Research Pharmacy Services · Portland, United States
  • Seattle Children's Investigational Drug Service, Pharmacy Department · Seattle, United States
  • Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância · Curitiba, Brazil
  • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
  • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
  • Fundação Pio XII - Hospital de Câncer de Barretos · Barretos, Brazil
  • Fakultni nemocnice v Motole · Prague, Czechia
  • Universitaetsklinikum Essen · Essen, Germany
  • All India Institute of Medical Sciences · New Delhi, India
  • Rajiv Gandhi Cancer Institute And Research Centre · New Delhi, India
  • Instytut Matki i Dziecka · Warsaw, Poland
  • Detska fakultna nemocnica s poliklinikou Banska Bystrica · Banská Bystrica, Slovakia
  • Hospital Infantil Universitario Niño Jesús · Madrid, Spain
  • Ege Universitesi Hastanesi · Izmir, Turkey (Türkiye)
Show 39 removed
  • MemorialCare Health System - Long Beach Medical Center · Long Beach, United States
  • Lucile Packard Children's Hospital · Palo Alto, United States
  • Children's National Hospital · Washington, United States
  • Johns Hopkins All Children's Hospital · Saint Petersburg, United States
  • Johns Hopkins All Children's Outpatient Care Center · Saint Petersburg, United States
  • Children's Healthcare of Atlanta at Egleston · Atlanta, United States
  • Children's Healthcare of Atlanta, Medical Office Building · Atlanta, United States
  • Norton Children's Hospital · Louisville, United States
  • Novak Center for Children's Health · Louisville, United States
  • University of Mississippi Medical Center · Jackson, United States
  • Washington University School of Medicine · Saint Louis, United States
  • Montefiore Medical Center · Bronx, United States
  • John R. Oishei Childrens Hospital · Buffalo, United States
  • Roswell Park Cancer Institute · Buffalo, United States
  • UPMC Children's Hospital of Pittsburgh · Pittsburgh, United States
  • Children's Blood and Cancer Center · Austin, United States
  • Dell Children's Medical Center · Austin, United States
  • Hospital Pequeno Principe / A ssociacao Hospitalar de Protecao a Infancia · Curitiba, Brazil
  • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
  • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
  • Fundação Pio XII - Hospital de Câncer de Barretos · Barretos, Brazil
  • Hospital Santa Marcelina · São Paulo, Brazil
  • Stollery Children's Hospital · Edmonton, Canada
  • Fakultni nemocnice v Motole · Praha, Czechia
  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest · Bordeaux, France
  • Centre Leon Berard · Lyon, France
  • Centre Leon Berard · Lyon, France
  • Gustave Roussy · Villejuif, France
  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone · Marseille, France
  • Universitätsklinikum Essen · Essen, Germany
  • …and 9 more on the registry record
Oct 7, 2026
Study completion
Oct 18, 2025→Aug 6, 2025 (actual)
Oct 7, 2026
Primary outcomes
1 edited, 10 added, 3 removed
What changed in the outcomes
  • EditedPhase 2 open-label, randomized: Event-free survival Free Survival (EFS) basedBased on Investigator assessment.AssessmentTime frame: Baseline to Month 24. → From date of randomization up to objective PD, diagnosis of secondary malignancy or death, whichever occurred first (maximum of approximately 14 months)
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Cycle 1 (21 days)
  • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Treatment-emergent AEs, Treatment-emergent Serious AEs (SAEs), Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Hematology ParametersTime frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Chemistry ParametersTime frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in Electrocardiogram (ECG) ParametersTime frame: Baseline (pre-treatment) up to Cycle 3 (63 days)
  • AddedPhase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood PressureTime frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 24.2 months)
  • AddedPhase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Pulse RateTime frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Clinically Significant Changes in Glycosylated Hemoglobin (HbA1c)Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Expansion Cohorts: Objective Response (OR) Rate Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
  • AddedTSC: OR Rate Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
  • RemovedPhase 1: First Cycle Dose-Limiting Toxicities (DLT)Time frame: First cycle (cycle length is approximately 21 days)
  • RemovedPhase 1: Dose Expansion Parts: Frequency of adverse eventsTime frame: At least 28 days after last dose
  • RemovedPhase 1: Dose Expansion Parts: Percentage of Participants With Complete Response or Partial ResponseTime frame: Through the end of treatment (up to at least 28 days after last dose)
Oct 7, 2026
Documents
Secondary outcomes
3 edited, 27 added, 39 more
What changed in the outcomes
  • EditedPhase 2 open-label, randomized: Event-free survivalFree Survival (EFS) assessed by an independent review committee.Based on Blinded Independent Review Committee (BIRC) AssessmentTime frame: Baseline to Month 24. → First date of randomization to the date of first objective PD, diagnosis of secondary malignancy, death due to any cause (maximum of approximately 14 months)
  • EditedPhase 1, Dose Expansion Cohorts and Phase 2TSC: Progression -Free Survival (PFS) Based on Investigator AssessmentTime frame: Up to 2 years → First dose of study treatment (Day 1) up to objective PD or death due to any cause, whichever occurred first (maximum of approximately 25 months)
  • EditedPhase 1, Dose Expansion Cohorts and Phase 2TSC: Overall Survival (OS)Time frame: Up to 2 years → First dose of study treatment (Day 1) up to death due to any cause (maximum of approximately 25 months)
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, and Maximum Grade 3 or 4 and 5 AEs by CTCAE v4.03Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Hematology ParametersTime frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Chemistry ParametersTime frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG ParametersTime frame: Baseline (pre-treatment) up to Cycle 3 (63 days)
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Blood PressureTime frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Pulse RateTime frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
  • AddedPhase 1: Maximum Plasma Concentration (Cmax) at Steady-State of Palbociclib, TMZ, IRN, SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
  • AddedPhase 1: Time to Reach Cmax (Tmax) of Palbociclib, TMZ, IRN SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
  • AddedPhase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) of Palbociclib, TMZ, IRN SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
  • AddedPhase 1: Pre-dose Plasma Concentration (Ctrough) at Steady-State of Palbociclib, TMZ, IRN SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5 or TMZ IV- PRD C1D5, C2D5
  • AddedPhase 1: Clearance of Palbociclib, TMZ, IRN SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: OR Rate Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
  • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Duration of Response (DOR) Based on Investigator AssessmentTime frame: From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)
  • AddedPhase 1, Dose Expansion Cohorts and TSC: DOR Based on Investigator AssessmentTime frame: From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)
  • AddedPhase 2: OR Rate Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to maximum of approximately 14 months
  • AddedPhase 2: Comparison of Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Assessment With Magnetic Resonance Imaging (MRI)/ Computed Tomography (CT) Assessment for ORTime frame: Cycle 4
  • AddedPhase 2: PFS Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to PD or death due to any cause, whichever occurred (maximum of approximately 14 months)
  • AddedPhase 2: OSTime frame: First dose of study treatment (Day 1) up to date of death due to any cause (maximum of approximately 76 months)
  • AddedPhase 2: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 9.5 months)
  • AddedPhase 2: Cmax at Steady-State of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
  • AddedPhase 2: Tmax of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
  • AddedPhase 2: AUCtau,ss of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
  • AddedPhase 2: Ctrough at Steady-State of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38 : PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5; or TMZ IV- PRD C1D5, C2D5
  • AddedPhase 2: Clearance of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
  • AddedPhase 2: Change From Baseline of Patient Reported Outcomes (PROMIS) Parent Proxy Profile v2.0 - Profile-25 Scale Score for Age >=5 to <=17 Years at Cycles 2 and 4Time frame: Baseline, Cycles 2 and 4
  • AddedPhase 2: Change From Baseline of PROMIS Pediatric Profile v2.0 - Profile-25 Scale Score for Age >=8 to <=17 Years at Cycles 2 and 4Time frame: Baseline, Cycles 2 and 4
  • AddedPhase 2: Change From Baseline of PROMIS-29 Profile v2.1 Scale Score for Age >=18 Years at Cycles 2 and 4Time frame: Baseline, Cycles 2 and 4
  • …and 39 more, on the record history on ClinicalTrials.gov ↗
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Active, not recruiting→Completed
    Results posted
    22 sites added, 39 sites removed; no longer in France
    Show 22 added (10 United States, 4 Brazil, 2 India, 1 Czechia, 1 Germany, 1 Poland, 1 Slovakia, 1 Spain, 1 Turkey (Türkiye))
    • Children's Hospital Los Angeles Pharmacy Department · Los Angeles, United States
    • UCSF Benioff Children's Hospital Investigational Pharmacy · San Francisco, United States
    • Children's National Hospital · Washington D.C., United States
    • Johns Hopkins All Children's Hospital · St. Petersburg, United States
    • Johns Hopkins All Children's Outpatient Care Center · St. Petersburg, United States
    • Children's Healthcare of Atlanta at Arthur M. Blank Hospital · Atlanta, United States
    • Washington University School of Medicine · St Louis, United States
    • CINJ Research Pharmacy · New Brunswick, United States
    • OHSU- Research Pharmacy Services · Portland, United States
    • Seattle Children's Investigational Drug Service, Pharmacy Department · Seattle, United States
    • Hospital Pequeno Príncipe / Associação Hospitalar de Proteção à Infância · Curitiba, Brazil
    • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
    • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
    • Fundação Pio XII - Hospital de Câncer de Barretos · Barretos, Brazil
    • Fakultni nemocnice v Motole · Prague, Czechia
    • Universitaetsklinikum Essen · Essen, Germany
    • All India Institute of Medical Sciences · New Delhi, India
    • Rajiv Gandhi Cancer Institute And Research Centre · New Delhi, India
    • Instytut Matki i Dziecka · Warsaw, Poland
    • Detska fakultna nemocnica s poliklinikou Banska Bystrica · Banská Bystrica, Slovakia
    • Hospital Infantil Universitario Niño Jesús · Madrid, Spain
    • Ege Universitesi Hastanesi · Izmir, Turkey (Türkiye)
    Show 39 removed
    • MemorialCare Health System - Long Beach Medical Center · Long Beach, United States
    • Lucile Packard Children's Hospital · Palo Alto, United States
    • Children's National Hospital · Washington, United States
    • Johns Hopkins All Children's Hospital · Saint Petersburg, United States
    • Johns Hopkins All Children's Outpatient Care Center · Saint Petersburg, United States
    • Children's Healthcare of Atlanta at Egleston · Atlanta, United States
    • Children's Healthcare of Atlanta, Medical Office Building · Atlanta, United States
    • Norton Children's Hospital · Louisville, United States
    • Novak Center for Children's Health · Louisville, United States
    • University of Mississippi Medical Center · Jackson, United States
    • Washington University School of Medicine · Saint Louis, United States
    • Montefiore Medical Center · Bronx, United States
    • John R. Oishei Childrens Hospital · Buffalo, United States
    • Roswell Park Cancer Institute · Buffalo, United States
    • UPMC Children's Hospital of Pittsburgh · Pittsburgh, United States
    • Children's Blood and Cancer Center · Austin, United States
    • Dell Children's Medical Center · Austin, United States
    • Hospital Pequeno Principe / A ssociacao Hospitalar de Protecao a Infancia · Curitiba, Brazil
    • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
    • Hospital de Clinicas de Porto Alegre · Porto Alegre, Brazil
    • Fundação Pio XII - Hospital de Câncer de Barretos · Barretos, Brazil
    • Hospital Santa Marcelina · São Paulo, Brazil
    • Stollery Children's Hospital · Edmonton, Canada
    • Fakultni nemocnice v Motole · Praha, Czechia
    • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest · Bordeaux, France
    • Centre Leon Berard · Lyon, France
    • Centre Leon Berard · Lyon, France
    • Gustave Roussy · Villejuif, France
    • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone · Marseille, France
    • Universitätsklinikum Essen · Essen, Germany
    • …and 9 more on the registry record
    Study completion Oct 18, 2025→Aug 6, 2025 (now actual)
    Primary outcomes 1 edited, 10 added, 3 removed
    What changed in the outcomes
    • EditedPhase 2 open-label, randomized: Event-free survival Free Survival (EFS) basedBased on Investigator assessment.AssessmentTime frame: Baseline to Month 24. → From date of randomization up to objective PD, diagnosis of secondary malignancy or death, whichever occurred first (maximum of approximately 14 months)
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Cycle 1 (21 days)
    • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Treatment-emergent AEs, Treatment-emergent Serious AEs (SAEs), Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Hematology ParametersTime frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Maximum CTCAE Grade in Chemistry ParametersTime frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Post-Baseline and Maximum Change From Baseline in Electrocardiogram (ECG) ParametersTime frame: Baseline (pre-treatment) up to Cycle 3 (63 days)
    • AddedPhase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Blood PressureTime frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 24.2 months)
    • AddedPhase 1, Dose Expansion Cohorts and TSC: Maximum Change From Baseline in Vital Signs Parameter- Pulse RateTime frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Expansion Cohorts and TSC: Number of Participants With Clinically Significant Changes in Glycosylated Hemoglobin (HbA1c)Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Expansion Cohorts: Objective Response (OR) Rate Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
    • AddedTSC: OR Rate Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
    • RemovedPhase 1: First Cycle Dose-Limiting Toxicities (DLT)Time frame: First cycle (cycle length is approximately 21 days)
    • RemovedPhase 1: Dose Expansion Parts: Frequency of adverse eventsTime frame: At least 28 days after last dose
    • RemovedPhase 1: Dose Expansion Parts: Percentage of Participants With Complete Response or Partial ResponseTime frame: Through the end of treatment (up to at least 28 days after last dose)
    Secondary outcomes 3 edited, 27 added, 39 more
    What changed in the outcomes
    • EditedPhase 2 open-label, randomized: Event-free survivalFree Survival (EFS) assessed by an independent review committee.Based on Blinded Independent Review Committee (BIRC) AssessmentTime frame: Baseline to Month 24. → First date of randomization to the date of first objective PD, diagnosis of secondary malignancy, death due to any cause (maximum of approximately 14 months)
    • EditedPhase 1, Dose Expansion Cohorts and Phase 2TSC: Progression -Free Survival (PFS) Based on Investigator AssessmentTime frame: Up to 2 years → First dose of study treatment (Day 1) up to objective PD or death due to any cause, whichever occurred first (maximum of approximately 25 months)
    • EditedPhase 1, Dose Expansion Cohorts and Phase 2TSC: Overall Survival (OS)Time frame: Up to 2 years → First dose of study treatment (Day 1) up to death due to any cause (maximum of approximately 25 months)
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, and Maximum Grade 3 or 4 and 5 AEs by CTCAE v4.03Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Hematology ParametersTime frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Maximum CTCAE Grade in Chemistry ParametersTime frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Number of Participants With Post-Baseline and Maximum Change From Baseline in ECG ParametersTime frame: Baseline (pre-treatment) up to Cycle 3 (63 days)
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Blood PressureTime frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Maximum Change From Baseline in Vital Signs Parameter- Pulse RateTime frame: Baseline (pre-treatment) up to end of study treatment (maximum up to approximately 25 months)
    • AddedPhase 1: Maximum Plasma Concentration (Cmax) at Steady-State of Palbociclib, TMZ, IRN, SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
    • AddedPhase 1: Time to Reach Cmax (Tmax) of Palbociclib, TMZ, IRN SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
    • AddedPhase 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau at Steady-State (AUCtau,ss) of Palbociclib, TMZ, IRN SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
    • AddedPhase 1: Pre-dose Plasma Concentration (Ctrough) at Steady-State of Palbociclib, TMZ, IRN SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5 or TMZ IV- PRD C1D5, C2D5
    • AddedPhase 1: Clearance of Palbociclib, TMZ, IRN SN-38, CTX and TOPOTime frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38, TOPO, CTX: PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: OR Rate Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to maximum of approximately 25 months
    • AddedPhase 1, Dose Escalation/Dose Determination Cohorts: Duration of Response (DOR) Based on Investigator AssessmentTime frame: From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)
    • AddedPhase 1, Dose Expansion Cohorts and TSC: DOR Based on Investigator AssessmentTime frame: From first documentation of OR to PD or death, whichever occurred earlier (maximum of approximately 25 months)
    • AddedPhase 2: OR Rate Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to maximum of approximately 14 months
    • AddedPhase 2: Comparison of Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) Assessment With Magnetic Resonance Imaging (MRI)/ Computed Tomography (CT) Assessment for ORTime frame: Cycle 4
    • AddedPhase 2: PFS Based on Investigator AssessmentTime frame: First dose of study treatment (Day 1) up to PD or death due to any cause, whichever occurred (maximum of approximately 14 months)
    • AddedPhase 2: OSTime frame: First dose of study treatment (Day 1) up to date of death due to any cause (maximum of approximately 76 months)
    • AddedPhase 2: Number of Participants With Treatment Emergent AEs, Treatment Emergent SAEs, Treatment Related AEs, Treatment Related SAEs and AEs of Maximum Grade 3 or 4 and 5Time frame: First dose of study treatment (Day 1) up to 35 days after last dose of study treatment (maximum up to approximately 9.5 months)
    • AddedPhase 2: Cmax at Steady-State of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
    • AddedPhase 2: Tmax of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D5: and C1D5 2, 4, 6, 8 & 24 hrs post dose (PTD) IRN, SN-38, TOPO, CTX: PRD C1D5; PTI C1D5; and 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5; 1, 4, 8 PTD C1D5; TMZ IV PRD C1D5; PTI C1D5; and 4, 8 PTD C1D5
    • AddedPhase 2: AUCtau,ss of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
    • AddedPhase 2: Ctrough at Steady-State of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; IRN, SN-38 : PRD C1D2/D5, C2D5; TMZ Oral- PRD C1D5, C2D5; or TMZ IV- PRD C1D5, C2D5
    • AddedPhase 2: Clearance of Palbociclib, TMZ, IRN and SN-38Time frame: Palbociclib: PRD C1D2/D5/D14, C2D5/D14; 2, 4, 6, 8 & 24 hrs PTD C1D5; IRN, SN-38 : PRD C1D2/D5, C2D5; PTI C1D5, C2D5; 4, 8 & 24 hrs PTD C1D5; TMZ Oral- PRD C1D5, C2D5; 1, 4, 8 & 24 hrs PTD C1D5; 1 hr PTD C2D5 or TMZ IV- PRD, PTI C1D5, C2D5
    • AddedPhase 2: Change From Baseline of Patient Reported Outcomes (PROMIS) Parent Proxy Profile v2.0 - Profile-25 Scale Score for Age >=5 to <=17 Years at Cycles 2 and 4Time frame: Baseline, Cycles 2 and 4
    • AddedPhase 2: Change From Baseline of PROMIS Pediatric Profile v2.0 - Profile-25 Scale Score for Age >=8 to <=17 Years at Cycles 2 and 4Time frame: Baseline, Cycles 2 and 4
    • AddedPhase 2: Change From Baseline of PROMIS-29 Profile v2.1 Scale Score for Age >=18 Years at Cycles 2 and 4Time frame: Baseline, Cycles 2 and 4
    • …and 39 more, on the record history on ClinicalTrials.gov ↗
    + 4 other changes: verification date, design details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03709680
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 17, 2018
Start date
May 24, 2019
Primary completion
Aug 26, 2024
Completion
Aug 6, 2025
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Temozolomide · Irinotecan · Topotecan · Cyclophosphamide

Start the discussion